[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMHtIMhvfAKNU8fyryGMnR7EZxgaKgNAFunKe3wy-FpE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"University Hospital, Grenoble",[4],812,false,156,51,321966,23,688,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Parkinson Disease",20,{"name":18,"count":19},"Obstructive Sleep Apnea",18,{"name":21,"count":22},"Healthy Volunteers",16,{"name":24,"count":25},"Healthy",15,{"name":27,"count":28},"Obstructive Sleep Apnea Syndrome",12,{"name":30,"count":31},"Stroke",11,{"name":33,"count":34},"Healthy Volunteer",10,{"name":36,"count":37},"Obesity",9,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04016246","Respiratory Effect of the LISA Method with Sedation by Propofol Versus Absence of Sedation.","2024-03-18","Propofol-Lipuro",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04552873","Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage","2024-12-03","Urea",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03570450","Regenerative Stem Cell Therapy for Stroke in Europe 1-RESSTORE1","2025-07-01","Adipose derived Stem Cell",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06611891","Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer","2025-10","68Ga-DOTATOC",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06212765","Oral Citrulline Supplementation in COPD Patients With Malnutrition","2026-01-25","L-citrulline",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05546879","Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC","2026-03-19","NP137",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06638710","Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient With Neurocognitive Disorders and Refusing Care.","2026-06-01","oral administration of midazolam or placebo",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06311604","Evaluation of the Safety of Inhaled Sedation With Isoflurane in Head Trauma Patients","2026-06-20","Isoflurane",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04526431","Tacrolimus Pharmacokinetic Subpopulations","2026-08-01","Dosage Forms",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT07078435","Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis","2026-09-30","Blood test",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,127,150,173,191,214,241,259,280,304,330,366,388,421,442,477,495,522,540,564,587,611,632,657,697,727,754,772,800,818,836,860,885,903,930,948,974,998,1022,1046,1070,1088,1111,1136,1162,1180,1209,1245,1281,1299,1326,1344,1369,1393,1419,1437,1463,1481,1507,1525,1553,1571,1589,1607,1633,1657,1680,1703,1721,1746,1771,1797,1822,1846,1871,1897,1922,1950,1968,1993,2018,2036,2054,2079,2102,2120,2145,2171,2189,2214,2239,2257,2275,2302,2326,2353,2378,2403,2428,2455,2481,2506,2530,2548,2572,2597,2620,2638,2656,2674,2692,2717,2743,2783,2807,2833,2857,2883,2906,2930,2955,2981,2999,3024,3048,3073,3091,3119,3137,3155,3180,3206,3224,3248,3266,3288,3314,3342,3360,3378,3396,3421,3446,3470,3488,3512,3536,3562,3584,3607,3631,3654,3672,3696,3720,3747,3772,3797,3815,3833,3861,3885,3911,3929,3954],{"intervention":98,"totalTrials":99,"cells":100},"Individualization of first voriconazole maintenance doses",1,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":125},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":103},[],{"trials":109,"activeCount":103},[],{"trials":111,"activeCount":99,"soonestReadout":117},[112],{"nctId":113,"briefTitle":114,"status":115,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":124},"NCT06582186","Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm","NOT_YET_RECRUITING",[94],"2027-10","2024-10",30,[121,122,123],"Aspergillosis Invasive","Fungal Infection","Hematologic Malignancy",[98],{"trials":126,"activeCount":103},[],{"intervention":58,"totalTrials":99,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":146,"NA":148},{"trials":130,"activeCount":103},[],{"trials":132,"activeCount":103},[],{"trials":134,"activeCount":103},[],{"trials":136,"activeCount":99,"soonestReadout":57},[137],{"nctId":55,"briefTitle":56,"status":138,"phases":139,"primaryCompletion":57,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"RECRUITING",[93],"2026-10","2025-01-06",25,[144],"Breast Cancer Metastatic",[58],{"trials":147,"activeCount":103},[],{"trials":149,"activeCount":103},[],{"intervention":43,"totalTrials":99,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":169,"NA":171},{"trials":153,"activeCount":103},[],{"trials":155,"activeCount":103},[],{"trials":157,"activeCount":103},[],{"trials":159,"activeCount":99,"soonestReadout":42},[160],{"nctId":40,"briefTitle":41,"status":161,"phases":162,"primaryCompletion":42,"completion":140,"start":163,"enrollment":164,"conditions":165,"interventions":167},"ACTIVE_NOT_RECRUITING",[93],"2019-10-07",233,[166],"Respiratory Distress Syndrome in Premature Infant",[43,168],"Placebos",{"trials":170,"activeCount":103},[],{"trials":172,"activeCount":103},[],{"intervention":168,"totalTrials":99,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":187,"NA":189},{"trials":176,"activeCount":103},[],{"trials":178,"activeCount":103},[],{"trials":180,"activeCount":103},[],{"trials":182,"activeCount":99,"soonestReadout":42},[183],{"nctId":40,"briefTitle":41,"status":161,"phases":184,"primaryCompletion":42,"completion":140,"start":163,"enrollment":164,"conditions":185,"interventions":186},[93],[166],[43,168],{"trials":188,"activeCount":103},[],{"trials":190,"activeCount":103},[],{"intervention":63,"totalTrials":99,"cells":192},{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":210,"NA":212},{"trials":194,"activeCount":103},[],{"trials":196,"activeCount":103},[],{"trials":198,"activeCount":103},[],{"trials":200,"activeCount":99,"soonestReadout":62},[201],{"nctId":60,"briefTitle":61,"status":115,"phases":202,"primaryCompletion":62,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":209},[93],"2026-09-25","2024-01-25",60,[207,208],"Chronic Obstructive Pulmonary Disease Severe","Malnutrition",[63],{"trials":211,"activeCount":103},[],{"trials":213,"activeCount":103},[],{"intervention":215,"totalTrials":99,"cells":216},"Volatile anesthetic",{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":237,"NA":239},{"trials":218,"activeCount":103},[],{"trials":220,"activeCount":103},[],{"trials":222,"activeCount":103},[],{"trials":224,"activeCount":99,"soonestReadout":229},[225],{"nctId":226,"briefTitle":227,"status":138,"phases":228,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT07166991","Anesthesia sTrategy foR Organ Procurement In braiN dEath",[93],"2028-09-01","2029-09-01","2026-02-17",270,[234],"Brain-dead Organ Donors",[215,236],"Opioid Anesthesia",{"trials":238,"activeCount":103},[],{"trials":240,"activeCount":103},[],{"intervention":236,"totalTrials":99,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":255,"NA":257},{"trials":244,"activeCount":103},[],{"trials":246,"activeCount":103},[],{"trials":248,"activeCount":103},[],{"trials":250,"activeCount":99,"soonestReadout":229},[251],{"nctId":226,"briefTitle":227,"status":138,"phases":252,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":253,"interventions":254},[93],[234],[215,236],{"trials":256,"activeCount":103},[],{"trials":258,"activeCount":103},[],{"intervention":73,"totalTrials":99,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":262,"activeCount":103},[],{"trials":264,"activeCount":103},[],{"trials":266,"activeCount":99,"soonestReadout":72},[267],{"nctId":70,"briefTitle":71,"status":138,"phases":268,"primaryCompletion":72,"completion":269,"start":270,"enrollment":119,"conditions":271,"interventions":273},[92],"2026-11-01","2025-07-08",[272],"Neurocognitive Disorders",[73],{"trials":275,"activeCount":103},[],{"trials":277,"activeCount":103},[],{"trials":279,"activeCount":103},[],{"intervention":281,"totalTrials":99,"cells":282},"embolization therapy",{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":298,"PHASE4":300,"NA":302},{"trials":284,"activeCount":103},[],{"trials":286,"activeCount":103},[],{"trials":288,"activeCount":99,"soonestReadout":293},[289],{"nctId":290,"briefTitle":291,"status":138,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":25,"conditions":295,"interventions":297},"NCT06611007","Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment",[91,92],"2028-07-15","2025-01-30",[296],"Osteoarthritis",[281],{"trials":299,"activeCount":103},[],{"trials":301,"activeCount":103},[],{"trials":303,"activeCount":103},[],{"intervention":305,"totalTrials":99,"cells":306},"Morphine hydrochloride",{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":308,"activeCount":103},[],{"trials":310,"activeCount":103},[],{"trials":312,"activeCount":99,"soonestReadout":317},[313],{"nctId":314,"briefTitle":315,"status":138,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":323},"NCT04427826","Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I\u002FIIa",[91,92],"2027-06-08","2028-01","2020-12-08",24,[322],"Chronic Obstructive Pulmonary Disease",[305],{"trials":325,"activeCount":103},[],{"trials":327,"activeCount":103},[],{"trials":329,"activeCount":103},[],{"intervention":331,"totalTrials":332,"cells":333},"Atezolizumab",2,{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":347,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":335,"activeCount":103},[],{"trials":337,"activeCount":99,"soonestReadout":67},[338],{"nctId":65,"briefTitle":66,"status":161,"phases":339,"primaryCompletion":67,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},[91],"2029-03-19","2023-03-15",43,[344],"Hepatocellular Carcinoma",[68,331,346],"Bevacizumab",{"trials":348,"activeCount":103},[349],{"nctId":350,"briefTitle":351,"status":352,"phases":353,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":358},"NCT05448677","Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma","TERMINATED",[92],"2024-03-08","2022-12-15",3,[344],[359,331,346],"Ezurpimtrostat",{"trials":361,"activeCount":103},[],{"trials":363,"activeCount":103},[],{"trials":365,"activeCount":103},[],{"intervention":346,"totalTrials":332,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":376,"PHASE3":382,"PHASE4":384,"NA":386},{"trials":369,"activeCount":103},[],{"trials":371,"activeCount":99,"soonestReadout":67},[372],{"nctId":65,"briefTitle":66,"status":161,"phases":373,"primaryCompletion":67,"completion":340,"start":341,"enrollment":342,"conditions":374,"interventions":375},[91],[344],[68,331,346],{"trials":377,"activeCount":103},[378],{"nctId":350,"briefTitle":351,"status":352,"phases":379,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":380,"interventions":381},[92],[344],[359,331,346],{"trials":383,"activeCount":103},[],{"trials":385,"activeCount":103},[],{"trials":387,"activeCount":103},[],{"intervention":68,"totalTrials":332,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":391,"activeCount":103},[],{"trials":393,"activeCount":99,"soonestReadout":67},[394,398],{"nctId":65,"briefTitle":66,"status":161,"phases":395,"primaryCompletion":67,"completion":340,"start":341,"enrollment":342,"conditions":396,"interventions":397},[91],[344],[68,331,346],{"nctId":399,"briefTitle":400,"status":401,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":342,"conditions":406,"interventions":408},"NCT05546853","Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma","COMPLETED",[91],"2024-12-09","2025-06-16","2023-03-28",[407],"Pancreatic Ductal Adenocarcinoma",[68,409,410,411,412],"Oxaliplatin","Irinotecan","Calcium levofolinate","5 FU",{"trials":414,"activeCount":103},[],{"trials":416,"activeCount":103},[],{"trials":418,"activeCount":103},[],{"trials":420,"activeCount":103},[],{"intervention":53,"totalTrials":99,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":424,"activeCount":103},[],{"trials":426,"activeCount":99,"soonestReadout":52},[427],{"nctId":50,"briefTitle":51,"status":138,"phases":428,"primaryCompletion":52,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":433},[91],"2027-07-01","2018-06-02",95,[30],[53],{"trials":435,"activeCount":103},[],{"trials":437,"activeCount":103},[],{"trials":439,"activeCount":103},[],{"trials":441,"activeCount":103},[],{"intervention":88,"totalTrials":332,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":445,"activeCount":103},[],{"trials":447,"activeCount":103},[],{"trials":449,"activeCount":103},[450],{"nctId":451,"briefTitle":452,"status":352,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":332,"conditions":456,"interventions":459},"NCT02653222","Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension",[92],"2018-02","2016-02",[457,458],"Hypertension Resistant to Conventional Therapy","Kidney Failure, Chronic",[88],{"trials":461,"activeCount":103},[],{"trials":463,"activeCount":103},[],{"trials":465,"activeCount":99,"soonestReadout":87},[466],{"nctId":85,"briefTitle":86,"status":115,"phases":467,"primaryCompletion":87,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":475},[95],"2027-09-30","2025-09-09",40,[472,473,474],"Endometriosis","Immunity","Microbiota",[88,476,476],"Stool samples",{"intervention":476,"totalTrials":99,"cells":478},{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":489},{"trials":480,"activeCount":103},[],{"trials":482,"activeCount":103},[],{"trials":484,"activeCount":103},[],{"trials":486,"activeCount":103},[],{"trials":488,"activeCount":103},[],{"trials":490,"activeCount":99,"soonestReadout":87},[491],{"nctId":85,"briefTitle":86,"status":115,"phases":492,"primaryCompletion":87,"completion":468,"start":469,"enrollment":470,"conditions":493,"interventions":494},[95],[472,473,474],[88,476,476],{"intervention":496,"totalTrials":99,"cells":497},"Enoxaparin standard dose",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":508},{"trials":499,"activeCount":103},[],{"trials":501,"activeCount":103},[],{"trials":503,"activeCount":103},[],{"trials":505,"activeCount":103},[],{"trials":507,"activeCount":103},[],{"trials":509,"activeCount":99,"soonestReadout":514},[510],{"nctId":511,"briefTitle":512,"status":115,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":520},"NCT07506473","Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial",[95],"2028-05","2026-04",540,[518,519],"Severe Trauma Patient","Venous Thromboembolism",[496,521],"Enoxaparin intermediate dose",{"intervention":521,"totalTrials":99,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":525,"activeCount":103},[],{"trials":527,"activeCount":103},[],{"trials":529,"activeCount":103},[],{"trials":531,"activeCount":103},[],{"trials":533,"activeCount":103},[],{"trials":535,"activeCount":99,"soonestReadout":514},[536],{"nctId":511,"briefTitle":512,"status":115,"phases":537,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":538,"interventions":539},[95],[518,519],[496,521],{"intervention":541,"totalTrials":99,"cells":542},"Isolation of anti-Pseudomonas antibodies from type B lymphocytes",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":551,"NA":553},{"trials":544,"activeCount":103},[],{"trials":546,"activeCount":103},[],{"trials":548,"activeCount":103},[],{"trials":550,"activeCount":103},[],{"trials":552,"activeCount":103},[],{"trials":554,"activeCount":99,"soonestReadout":140},[555],{"nctId":556,"briefTitle":557,"status":138,"phases":558,"primaryCompletion":140,"completion":140,"start":559,"enrollment":119,"conditions":560,"interventions":563},"NCT04335383","Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies",[],"2020-10-05",[561,562],"Pseudomonas Aeruginosa","Multi-antibiotic Resistance",[541],{"intervention":83,"totalTrials":99,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":567,"activeCount":103},[],{"trials":569,"activeCount":103},[],{"trials":571,"activeCount":103},[],{"trials":573,"activeCount":103},[],{"trials":575,"activeCount":103},[],{"trials":577,"activeCount":99,"soonestReadout":82},[578],{"nctId":80,"briefTitle":81,"status":138,"phases":579,"primaryCompletion":82,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":586},[],"2027-08-01","2020-07-28",180,[584,585],"Kidney Transplant Failure and Rejection","Immunosuppression-related Infectious Disease",[83],{"intervention":48,"totalTrials":99,"cells":588},{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":595,"PHASE4":597,"NA":599},{"trials":590,"activeCount":103},[],{"trials":592,"activeCount":103},[],{"trials":594,"activeCount":103},[],{"trials":596,"activeCount":103},[],{"trials":598,"activeCount":103},[],{"trials":600,"activeCount":99,"soonestReadout":47},[601],{"nctId":45,"briefTitle":46,"status":161,"phases":602,"primaryCompletion":47,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":610},[95],"2025-08-01","2020-12-03",52,[607,608,609],"Hyponatremia","Subarachnoid Hemorrhage","SIADH",[48],{"intervention":78,"totalTrials":99,"cells":612},{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":614,"activeCount":103},[],{"trials":616,"activeCount":103},[],{"trials":618,"activeCount":103},[],{"trials":620,"activeCount":103},[],{"trials":622,"activeCount":103},[],{"trials":624,"activeCount":99,"soonestReadout":77},[625],{"nctId":75,"briefTitle":76,"status":138,"phases":626,"primaryCompletion":77,"completion":627,"start":628,"enrollment":119,"conditions":629,"interventions":631},[95],"2027-03-20","2024-06-20",[630],"Traumatic Brain Injury",[78],{"intervention":633,"totalTrials":99,"cells":634},"Blood test 4 EDTA tubes",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":643,"NA":645},{"trials":636,"activeCount":103},[],{"trials":638,"activeCount":103},[],{"trials":640,"activeCount":103},[],{"trials":642,"activeCount":103},[],{"trials":644,"activeCount":103},[],{"trials":646,"activeCount":99,"soonestReadout":651},[647],{"nctId":648,"briefTitle":649,"status":115,"phases":650,"primaryCompletion":651,"completion":652,"start":653,"enrollment":119,"conditions":654,"interventions":656},"NCT06944873","Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases",[],"2028-04-30","2028-07-31","2026-07-01",[655],"Inflammatory Bowel Disease (IBD)",[633],{"intervention":658,"totalTrials":332,"cells":659},"Morphine",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":680,"NA":695},{"trials":661,"activeCount":103},[],{"trials":663,"activeCount":103},[],{"trials":665,"activeCount":103},[],{"trials":667,"activeCount":103},[668],{"nctId":669,"briefTitle":670,"status":401,"phases":671,"primaryCompletion":672,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":678},"NCT02410317","Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section",[93],"2021-08-28","2021-12-28","2015-02",101,[677],"Postoperative Pain",[679,658],"Ropivacaine",{"trials":681,"activeCount":103},[682],{"nctId":683,"briefTitle":684,"status":401,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":693},"NCT02095366","Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting",[94],"2016-04-10","2016-06-30","2013-08-02",194,[691,692],"Severe Traumatic Pain","Numeric Pain Rating Scale > 5 \u002F 10",[658,694],"Sufentanil",{"trials":696,"activeCount":103},[],{"intervention":694,"totalTrials":332,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":719,"NA":725},{"trials":700,"activeCount":103},[],{"trials":702,"activeCount":103},[],{"trials":704,"activeCount":103},[],{"trials":706,"activeCount":103},[707],{"nctId":708,"briefTitle":709,"status":401,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":470,"conditions":713,"interventions":717},"NCT01235637","Alfentanil Versus Sufentanil for Pain in Children During for Tracheal Suction",[93],"2012-06","2010-06",[714,658,715,716],"Child Comfort","Intensive Care Units","Pediatric",[718,694],"Alfentanil",{"trials":720,"activeCount":103},[721],{"nctId":683,"briefTitle":684,"status":401,"phases":722,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":723,"interventions":724},[94],[691,692],[658,694],{"trials":726,"activeCount":103},[],{"intervention":728,"totalTrials":99,"cells":729},"Valsartan",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":752},{"trials":731,"activeCount":103},[],{"trials":733,"activeCount":103},[],{"trials":735,"activeCount":103},[],{"trials":737,"activeCount":103},[],{"trials":739,"activeCount":103},[740],{"nctId":741,"briefTitle":742,"status":352,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":28,"conditions":747,"interventions":750},"NCT02058823","Intermittent Hypoxia 2: Cardiovascular and Metabolism",[94],"2014-07-17","2017-03-16","2013-08-07",[748,749,18],"Hypoxia","Sleep Apnea",[728,751],"Amlodipine",{"trials":753,"activeCount":103},[],{"intervention":751,"totalTrials":99,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":770},{"trials":757,"activeCount":103},[],{"trials":759,"activeCount":103},[],{"trials":761,"activeCount":103},[],{"trials":763,"activeCount":103},[],{"trials":765,"activeCount":103},[766],{"nctId":741,"briefTitle":742,"status":352,"phases":767,"primaryCompletion":744,"completion":745,"start":746,"enrollment":28,"conditions":768,"interventions":769},[94],[748,749,18],[728,751],{"trials":771,"activeCount":103},[],{"intervention":773,"totalTrials":99,"cells":774},"methylprednisolone",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":798},{"trials":776,"activeCount":103},[],{"trials":778,"activeCount":103},[],{"trials":780,"activeCount":103},[],{"trials":782,"activeCount":103},[],{"trials":784,"activeCount":103},[785],{"nctId":786,"briefTitle":787,"status":401,"phases":788,"primaryCompletion":789,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT01816334","Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica",[94],"2015-12","2016-01","2013-01",50,[794],"Sciatica",[773,796,797],"Ketoprofen","Sodium Chloride",{"trials":799,"activeCount":103},[],{"intervention":796,"totalTrials":99,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":810,"NA":816},{"trials":803,"activeCount":103},[],{"trials":805,"activeCount":103},[],{"trials":807,"activeCount":103},[],{"trials":809,"activeCount":103},[],{"trials":811,"activeCount":103},[812],{"nctId":786,"briefTitle":787,"status":401,"phases":813,"primaryCompletion":789,"completion":790,"start":791,"enrollment":792,"conditions":814,"interventions":815},[94],[794],[773,796,797],{"trials":817,"activeCount":103},[],{"intervention":797,"totalTrials":99,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":828,"NA":834},{"trials":821,"activeCount":103},[],{"trials":823,"activeCount":103},[],{"trials":825,"activeCount":103},[],{"trials":827,"activeCount":103},[],{"trials":829,"activeCount":103},[830],{"nctId":786,"briefTitle":787,"status":401,"phases":831,"primaryCompletion":789,"completion":790,"start":791,"enrollment":792,"conditions":832,"interventions":833},[94],[794],[773,796,797],{"trials":835,"activeCount":103},[],{"intervention":837,"totalTrials":99,"cells":838},"variation of mannitol dose",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":858},{"trials":840,"activeCount":103},[],{"trials":842,"activeCount":103},[],{"trials":844,"activeCount":103},[],{"trials":846,"activeCount":103},[],{"trials":848,"activeCount":103},[849],{"nctId":850,"briefTitle":851,"status":352,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":356,"conditions":855,"interventions":857},"NCT00795587","Comparison of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension and Cerebral Monitoring",[94],"2011-08","2008-10",[630,856],"Intracranial Hypertension",[837],{"trials":859,"activeCount":103},[],{"intervention":861,"totalTrials":99,"cells":862},"Rivaroxaban, Dabigatran",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":883},{"trials":864,"activeCount":103},[],{"trials":866,"activeCount":103},[],{"trials":868,"activeCount":103},[],{"trials":870,"activeCount":103},[],{"trials":872,"activeCount":103},[873],{"nctId":874,"briefTitle":875,"status":401,"phases":876,"primaryCompletion":877,"completion":878,"start":879,"enrollment":34,"conditions":880,"interventions":881},"NCT01210755","Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics",[94],"2011-03","2011-06","2010-11",[519],[861,882],"Dabigatran; Rivaroxaban",{"trials":884,"activeCount":103},[],{"intervention":882,"totalTrials":99,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":895,"NA":901},{"trials":888,"activeCount":103},[],{"trials":890,"activeCount":103},[],{"trials":892,"activeCount":103},[],{"trials":894,"activeCount":103},[],{"trials":896,"activeCount":103},[897],{"nctId":874,"briefTitle":875,"status":401,"phases":898,"primaryCompletion":877,"completion":878,"start":879,"enrollment":34,"conditions":899,"interventions":900},[94],[519],[861,882],{"trials":902,"activeCount":103},[],{"intervention":904,"totalTrials":99,"cells":905},"association of levocetirizine and tranexamic acid",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":928},{"trials":907,"activeCount":103},[],{"trials":909,"activeCount":103},[],{"trials":911,"activeCount":103},[],{"trials":913,"activeCount":103},[],{"trials":915,"activeCount":103},[916],{"nctId":917,"briefTitle":918,"status":919,"phases":920,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":924,"interventions":926},"NCT03789422","Tranexamic Acid and Spontaneous Chronic Urticaria","UNKNOWN",[94],"2022-09","2019-12-10",80,[925],"Chronic Spontaneous Urticaria",[904,927],"Levocetirizine only",{"trials":929,"activeCount":103},[],{"intervention":927,"totalTrials":99,"cells":931},{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":946},{"trials":933,"activeCount":103},[],{"trials":935,"activeCount":103},[],{"trials":937,"activeCount":103},[],{"trials":939,"activeCount":103},[],{"trials":941,"activeCount":103},[942],{"nctId":917,"briefTitle":918,"status":919,"phases":943,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":944,"interventions":945},[94],[925],[904,927],{"trials":947,"activeCount":103},[],{"intervention":949,"totalTrials":99,"cells":950},"Zopiclone",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":972},{"trials":952,"activeCount":103},[],{"trials":954,"activeCount":103},[],{"trials":956,"activeCount":103},[],{"trials":958,"activeCount":103},[],{"trials":960,"activeCount":103},[961],{"nctId":962,"briefTitle":963,"status":352,"phases":964,"primaryCompletion":965,"completion":966,"start":967,"enrollment":332,"conditions":968,"interventions":971},"NCT02820441","Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance",[94],"2017-09","2018-06","2016-05",[969,970],"Sleep Apnea, Central","Ventricular Dysfunction",[949],{"trials":973,"activeCount":103},[],{"intervention":975,"totalTrials":99,"cells":976},"Valsartant treatment",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":996},{"trials":978,"activeCount":103},[],{"trials":980,"activeCount":103},[],{"trials":982,"activeCount":103},[],{"trials":984,"activeCount":103},[],{"trials":986,"activeCount":103},[987],{"nctId":988,"briefTitle":989,"status":401,"phases":990,"primaryCompletion":991,"completion":992,"start":991,"enrollment":205,"conditions":993,"interventions":995},"NCT00409487","Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients",[94],"2006-12","2009-05",[994,18],"Hypertension,",[975],{"trials":997,"activeCount":103},[],{"intervention":999,"totalTrials":99,"cells":1000},"Dexmedetomidine",{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1007,"PHASE4":1009,"NA":1020},{"trials":1002,"activeCount":103},[],{"trials":1004,"activeCount":103},[],{"trials":1006,"activeCount":103},[],{"trials":1008,"activeCount":103},[],{"trials":1010,"activeCount":103},[1011],{"nctId":1012,"briefTitle":1013,"status":401,"phases":1014,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":16,"conditions":1017,"interventions":1019},"NCT02537366","Dexmedetomidine for Non-invasive Ventilation After Chest Trauma",[94],"2017-02","2015-09",[1018],"Thoracic Injuries",[999],{"trials":1021,"activeCount":103},[],{"intervention":1023,"totalTrials":99,"cells":1024},"Gadolinium",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1044},{"trials":1026,"activeCount":103},[],{"trials":1028,"activeCount":103},[],{"trials":1030,"activeCount":103},[],{"trials":1032,"activeCount":103},[],{"trials":1034,"activeCount":103},[1035],{"nctId":1036,"briefTitle":1037,"status":352,"phases":1038,"primaryCompletion":1039,"completion":1039,"start":1040,"enrollment":11,"conditions":1041,"interventions":1043},"NCT02530931","Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease",[94],"2020-09","2016-03-16",[1042],"Meniere's Disease",[1023],{"trials":1045,"activeCount":103},[],{"intervention":1047,"totalTrials":99,"cells":1048},"20% mannitol",{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1068},{"trials":1050,"activeCount":103},[],{"trials":1052,"activeCount":103},[],{"trials":1054,"activeCount":103},[],{"trials":1056,"activeCount":103},[],{"trials":1058,"activeCount":103},[1059],{"nctId":1060,"briefTitle":1061,"status":401,"phases":1062,"completion":1063,"start":1064,"enrollment":16,"conditions":1065,"interventions":1066},"NCT00447018","Mannitol Versus Hypertonic Saline Solution in the Treatment of Elevated Intracranial Pressure",[94],"2005-06","2002-10",[856],[1047,1067],"7.45% hypertonic saline solution",{"trials":1069,"activeCount":103},[],{"intervention":1067,"totalTrials":99,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1086},{"trials":1073,"activeCount":103},[],{"trials":1075,"activeCount":103},[],{"trials":1077,"activeCount":103},[],{"trials":1079,"activeCount":103},[],{"trials":1081,"activeCount":103},[1082],{"nctId":1060,"briefTitle":1061,"status":401,"phases":1083,"completion":1063,"start":1064,"enrollment":16,"conditions":1084,"interventions":1085},[94],[856],[1047,1067],{"trials":1087,"activeCount":103},[],{"intervention":1089,"totalTrials":99,"cells":1090},"Gadoteric acid",{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1097,"PHASE4":1099,"NA":1109},{"trials":1092,"activeCount":103},[],{"trials":1094,"activeCount":103},[],{"trials":1096,"activeCount":103},[],{"trials":1098,"activeCount":103},[],{"trials":1100,"activeCount":103},[1101],{"nctId":1102,"briefTitle":1103,"status":352,"phases":1104,"primaryCompletion":1039,"completion":1039,"start":1105,"enrollment":142,"conditions":1106,"interventions":1108},"NCT02529475","Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)",[94],"2016-02-01",[1107],"Meniere Disease",[1089],{"trials":1110,"activeCount":103},[],{"intervention":1112,"totalTrials":99,"cells":1113},"Temocillin",{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1134},{"trials":1115,"activeCount":103},[],{"trials":1117,"activeCount":103},[],{"trials":1119,"activeCount":103},[],{"trials":1121,"activeCount":103},[],{"trials":1123,"activeCount":103},[1124],{"nctId":1125,"briefTitle":1126,"status":919,"phases":1127,"primaryCompletion":1128,"completion":1129,"start":1130,"enrollment":142,"conditions":1131,"interventions":1133},"NCT02681263","Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae",[94],"2018-04","2018-09","2016-04",[1132],"Urinary Tract Infections",[1112],{"trials":1135,"activeCount":103},[],{"intervention":1137,"totalTrials":99,"cells":1138},"3 % hypertonic saline up to 72H",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1147,"NA":1160},{"trials":1140,"activeCount":103},[],{"trials":1142,"activeCount":103},[],{"trials":1144,"activeCount":103},[],{"trials":1146,"activeCount":103},[],{"trials":1148,"activeCount":103},[1149],{"nctId":1150,"briefTitle":1151,"status":401,"phases":1152,"primaryCompletion":1153,"completion":1153,"start":1154,"enrollment":1155,"conditions":1156,"interventions":1158},"NCT02538458","Efficacy and Safety of 3% Hypertonic Saline Inhalation (24h vs 72h) to Treat Acute Bronchiolitis in Hospitalized Infants",[94],"2016-03","2014-11",120,[1157],"Bronchiolitis",[1137,1159],"3 % hypertonic saline up to 24H",{"trials":1161,"activeCount":103},[],{"intervention":1159,"totalTrials":99,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1178},{"trials":1165,"activeCount":103},[],{"trials":1167,"activeCount":103},[],{"trials":1169,"activeCount":103},[],{"trials":1171,"activeCount":103},[],{"trials":1173,"activeCount":103},[1174],{"nctId":1150,"briefTitle":1151,"status":401,"phases":1175,"primaryCompletion":1153,"completion":1153,"start":1154,"enrollment":1155,"conditions":1176,"interventions":1177},[94],[1157],[1137,1159],{"trials":1179,"activeCount":103},[],{"intervention":679,"totalTrials":332,"cells":1181},{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1205,"NA":1207},{"trials":1183,"activeCount":103},[],{"trials":1185,"activeCount":103},[],{"trials":1187,"activeCount":103},[],{"trials":1189,"activeCount":103},[1190,1201],{"nctId":1191,"briefTitle":1192,"status":401,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":1194,"enrollment":205,"conditions":1196,"interventions":1199},"NCT01743794","Continuous Wound Infusion in Lumbar or Thoracic Surgery",[92,93],"2011-01","2012-07",[1197,1198],"Lumbar Spine Surgery","Thoracic Spine Surgery",[679,1200],"Saline solution 0.9%",{"nctId":669,"briefTitle":670,"status":401,"phases":1202,"primaryCompletion":672,"completion":673,"start":674,"enrollment":675,"conditions":1203,"interventions":1204},[93],[677],[679,658],{"trials":1206,"activeCount":103},[],{"trials":1208,"activeCount":103},[],{"intervention":1210,"totalTrials":332,"cells":1211},"bosentan",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1228,"PHASE4":1241,"NA":1243},{"trials":1213,"activeCount":103},[],{"trials":1215,"activeCount":103},[],{"trials":1217,"activeCount":103},[1218],{"nctId":1219,"briefTitle":1220,"status":401,"phases":1221,"primaryCompletion":1222,"completion":1222,"start":1223,"enrollment":1224,"conditions":1225,"interventions":1227},"NCT00777985","Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea",[92],"2012-01","2007-12",19,[18,1226],"Hypertension",[1210],{"trials":1229,"activeCount":103},[1230],{"nctId":1231,"briefTitle":1232,"status":919,"phases":1233,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1240},"NCT02377271","ENDOTHELION Study Group: Effect of Bosentan in NAION Patients",[93],"2023-12","2025-12","2015-08",86,[1239],"Ischemic Optic Neuropathy",[1210],{"trials":1242,"activeCount":103},[],{"trials":1244,"activeCount":103},[],{"intervention":1246,"totalTrials":332,"cells":1247},"NaCl 0.9%",{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1252,"PHASE3":1263,"PHASE4":1277,"NA":1279},{"trials":1249,"activeCount":103},[],{"trials":1251,"activeCount":103},[],{"trials":1253,"activeCount":103},[1254],{"nctId":1255,"briefTitle":1256,"status":401,"phases":1257,"primaryCompletion":1194,"completion":1194,"start":1258,"enrollment":16,"conditions":1259,"interventions":1260},"NCT01082484","Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers",[91,92],"2010-01",[24],[1261,1262,1246],"treprostinil","iloprost",{"trials":1264,"activeCount":103},[1265],{"nctId":1266,"briefTitle":1267,"status":401,"phases":1268,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1275},"NCT03218722","Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma",[93],"2021-08-31","2022-06-15","2017-12-29",350,[1274],"Shock, Hemorrhagic",[1276,1246],"Pro-Thrombin Concentrate Complex",{"trials":1278,"activeCount":103},[],{"trials":1280,"activeCount":103},[],{"intervention":1200,"totalTrials":99,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1295,"NA":1297},{"trials":1284,"activeCount":103},[],{"trials":1286,"activeCount":103},[],{"trials":1288,"activeCount":103},[],{"trials":1290,"activeCount":103},[1291],{"nctId":1191,"briefTitle":1192,"status":401,"phases":1292,"primaryCompletion":1194,"completion":1195,"start":1194,"enrollment":205,"conditions":1293,"interventions":1294},[92,93],[1197,1198],[679,1200],{"trials":1296,"activeCount":103},[],{"trials":1298,"activeCount":103},[],{"intervention":1300,"totalTrials":99,"cells":1301},"Oral dietary supplements (563 kcal\u002Fd), RESPIFOR",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1322,"NA":1324},{"trials":1303,"activeCount":103},[],{"trials":1305,"activeCount":103},[],{"trials":1307,"activeCount":103},[],{"trials":1309,"activeCount":103},[1310],{"nctId":1311,"briefTitle":1312,"status":401,"phases":1313,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1320},"NCT00230984","IRAD2 : Patients With Respiratory Failure at Home",[93],"2008-06","2003-04",200,[1318,1319],"Chronic Respiratory Failure","Nutritional Depletion",[1300,1321],"160 mg\u002Fd of oral testosterone undecanoate in men, 80 mg\u002Fd in women",{"trials":1323,"activeCount":103},[],{"trials":1325,"activeCount":103},[],{"intervention":1321,"totalTrials":99,"cells":1327},{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1334,"PHASE4":1340,"NA":1342},{"trials":1329,"activeCount":103},[],{"trials":1331,"activeCount":103},[],{"trials":1333,"activeCount":103},[],{"trials":1335,"activeCount":103},[1336],{"nctId":1311,"briefTitle":1312,"status":401,"phases":1337,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1338,"interventions":1339},[93],[1318,1319],[1300,1321],{"trials":1341,"activeCount":103},[],{"trials":1343,"activeCount":103},[],{"intervention":1345,"totalTrials":99,"cells":1346},"Apixaban",{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1365,"NA":1367},{"trials":1348,"activeCount":103},[],{"trials":1350,"activeCount":103},[],{"trials":1352,"activeCount":103},[],{"trials":1354,"activeCount":103},[1355],{"nctId":1356,"briefTitle":1357,"status":401,"phases":1358,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1364},"NCT02066454","Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs",[93],"2016-07-12","2014-06-05",108,[1363,519],"Myeloma",[1345],{"trials":1366,"activeCount":103},[],{"trials":1368,"activeCount":103},[],{"intervention":1370,"totalTrials":99,"cells":1371},"Valganciclovir",{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1389,"NA":1391},{"trials":1373,"activeCount":103},[],{"trials":1375,"activeCount":103},[],{"trials":1377,"activeCount":103},[],{"trials":1379,"activeCount":103},[1380],{"nctId":1381,"briefTitle":1382,"status":352,"phases":1383,"completion":1223,"start":1384,"enrollment":470,"conditions":1385,"interventions":1388},"NCT00237653","MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus",[93],"2004-02",[1386,1387],"Cytomegalovirus Infections","Inflammatory Bowel Diseases",[1370],{"trials":1390,"activeCount":103},[],{"trials":1392,"activeCount":103},[],{"intervention":1394,"totalTrials":99,"cells":1395},"Sildenafil 40 mg",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1415,"NA":1417},{"trials":1397,"activeCount":103},[],{"trials":1399,"activeCount":103},[],{"trials":1401,"activeCount":103},[],{"trials":1403,"activeCount":103},[1404],{"nctId":1405,"briefTitle":1406,"status":401,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1413},"NCT02050360","\"As Required\" Oral Sildenafil in Raynaud's Phenomenon",[92,93],"2015-05","2013-11",41,[1412],"Raynaud's Phenomenon",[1394,1414],"Sildenafil 80 mg",{"trials":1416,"activeCount":103},[],{"trials":1418,"activeCount":103},[],{"intervention":1414,"totalTrials":99,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1427,"PHASE4":1433,"NA":1435},{"trials":1422,"activeCount":103},[],{"trials":1424,"activeCount":103},[],{"trials":1426,"activeCount":103},[],{"trials":1428,"activeCount":103},[1429],{"nctId":1405,"briefTitle":1406,"status":401,"phases":1430,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":1431,"interventions":1432},[92,93],[1412],[1394,1414],{"trials":1434,"activeCount":103},[],{"trials":1436,"activeCount":103},[],{"intervention":1438,"totalTrials":99,"cells":1439},"CHOP21",{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1446,"PHASE4":1459,"NA":1461},{"trials":1441,"activeCount":103},[],{"trials":1443,"activeCount":103},[],{"trials":1445,"activeCount":103},[],{"trials":1447,"activeCount":103},[1448],{"nctId":1449,"briefTitle":1450,"status":401,"phases":1451,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":431,"conditions":1455,"interventions":1457},"NCT00970385","Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma",[93],"2002-12","2008-09","1995-01",[1456],"Peripheral T Cell Lymphoma",[1438,1458],"VIP\u002FABVD",{"trials":1460,"activeCount":103},[],{"trials":1462,"activeCount":103},[],{"intervention":1458,"totalTrials":99,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1477,"NA":1479},{"trials":1466,"activeCount":103},[],{"trials":1468,"activeCount":103},[],{"trials":1470,"activeCount":103},[],{"trials":1472,"activeCount":103},[1473],{"nctId":1449,"briefTitle":1450,"status":401,"phases":1474,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":431,"conditions":1475,"interventions":1476},[93],[1456],[1438,1458],{"trials":1478,"activeCount":103},[],{"trials":1480,"activeCount":103},[],{"intervention":1482,"totalTrials":99,"cells":1483},"Ringer Lactate (10ml\u002Fkg) fluid expansion",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1490,"PHASE4":1503,"NA":1505},{"trials":1485,"activeCount":103},[],{"trials":1487,"activeCount":103},[],{"trials":1489,"activeCount":103},[],{"trials":1491,"activeCount":103},[1492],{"nctId":1493,"briefTitle":1494,"status":401,"phases":1495,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":119,"conditions":1498,"interventions":1501},"NCT02782520","Comparison of the Effects of an Hypertonic Solution With Ringer Lactate on Right Ventricular Function Following Cardiac Surgery",[93],"2017-10","2016-08",[1499,1500],"Right Ventricular Impaired Function","Hypovolemia",[1482,1502],"Hypertonic saline (3ml\u002Fkg) fluid expansion",{"trials":1504,"activeCount":103},[],{"trials":1506,"activeCount":103},[],{"intervention":1502,"totalTrials":99,"cells":1508},{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1521,"NA":1523},{"trials":1510,"activeCount":103},[],{"trials":1512,"activeCount":103},[],{"trials":1514,"activeCount":103},[],{"trials":1516,"activeCount":103},[1517],{"nctId":1493,"briefTitle":1494,"status":401,"phases":1518,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":119,"conditions":1519,"interventions":1520},[93],[1499,1500],[1482,1502],{"trials":1522,"activeCount":103},[],{"trials":1524,"activeCount":103},[],{"intervention":1526,"totalTrials":99,"cells":1527},"Arnica montana, 5 CH",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1549,"NA":1551},{"trials":1529,"activeCount":103},[],{"trials":1531,"activeCount":103},[],{"trials":1533,"activeCount":103},[],{"trials":1535,"activeCount":103},[1536],{"nctId":1537,"briefTitle":1538,"status":352,"phases":1539,"completion":1540,"start":1541,"enrollment":1542,"conditions":1543,"interventions":1545},"NCT00222365","Homeopathy Assessment in Terms of the Consumption of Analgesics After Knee Ligamentoplasty",[93],"2006-05","2003-12",165,[1544],"Pain",[1526,1546,1547,1548],"Bryonia alba, 5 CH","Hypericum perforatum, 5 CH","Ruta graveolens, 3 DH",{"trials":1550,"activeCount":103},[],{"trials":1552,"activeCount":103},[],{"intervention":1546,"totalTrials":99,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1561,"PHASE4":1567,"NA":1569},{"trials":1556,"activeCount":103},[],{"trials":1558,"activeCount":103},[],{"trials":1560,"activeCount":103},[],{"trials":1562,"activeCount":103},[1563],{"nctId":1537,"briefTitle":1538,"status":352,"phases":1564,"completion":1540,"start":1541,"enrollment":1542,"conditions":1565,"interventions":1566},[93],[1544],[1526,1546,1547,1548],{"trials":1568,"activeCount":103},[],{"trials":1570,"activeCount":103},[],{"intervention":1547,"totalTrials":99,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1579,"PHASE4":1585,"NA":1587},{"trials":1574,"activeCount":103},[],{"trials":1576,"activeCount":103},[],{"trials":1578,"activeCount":103},[],{"trials":1580,"activeCount":103},[1581],{"nctId":1537,"briefTitle":1538,"status":352,"phases":1582,"completion":1540,"start":1541,"enrollment":1542,"conditions":1583,"interventions":1584},[93],[1544],[1526,1546,1547,1548],{"trials":1586,"activeCount":103},[],{"trials":1588,"activeCount":103},[],{"intervention":1548,"totalTrials":99,"cells":1590},{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1603,"NA":1605},{"trials":1592,"activeCount":103},[],{"trials":1594,"activeCount":103},[],{"trials":1596,"activeCount":103},[],{"trials":1598,"activeCount":103},[1599],{"nctId":1537,"briefTitle":1538,"status":352,"phases":1600,"completion":1540,"start":1541,"enrollment":1542,"conditions":1601,"interventions":1602},[93],[1544],[1526,1546,1547,1548],{"trials":1604,"activeCount":103},[],{"trials":1606,"activeCount":103},[],{"intervention":1608,"totalTrials":99,"cells":1609},"levetiracetam",{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1629,"NA":1631},{"trials":1611,"activeCount":103},[],{"trials":1613,"activeCount":103},[],{"trials":1615,"activeCount":103},[],{"trials":1617,"activeCount":103},[1618],{"nctId":1619,"briefTitle":1620,"status":352,"phases":1621,"primaryCompletion":1622,"completion":1622,"start":1623,"enrollment":1624,"conditions":1625,"interventions":1628},"NCT00376766","Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)",[93],"2008-04","2007-02",112,[1626,1627],"Epilepsy","Drug Resistant",[1608],{"trials":1630,"activeCount":103},[],{"trials":1632,"activeCount":103},[],{"intervention":1634,"totalTrials":99,"cells":1635},"Montelukast 10mg",{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1640,"PHASE3":1642,"PHASE4":1653,"NA":1655},{"trials":1637,"activeCount":103},[],{"trials":1639,"activeCount":103},[],{"trials":1641,"activeCount":103},[],{"trials":1643,"activeCount":103},[1644],{"nctId":1645,"briefTitle":1646,"status":352,"phases":1647,"primaryCompletion":1648,"completion":1648,"start":1649,"enrollment":99,"conditions":1650,"interventions":1652},"NCT03545997","Montelukast for Patients With Obstructive Sleep Apnea Syndrome",[93],"2020-03-20","2019-11-29",[1651],"Sleep Apnea, Obstructive",[1634],{"trials":1654,"activeCount":103},[],{"trials":1656,"activeCount":103},[],{"intervention":1658,"totalTrials":99,"cells":1659},"Micafungin",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1676,"NA":1678},{"trials":1661,"activeCount":103},[],{"trials":1663,"activeCount":103},[],{"trials":1665,"activeCount":103},[],{"trials":1667,"activeCount":103},[1668],{"nctId":1669,"briefTitle":1670,"status":401,"phases":1671,"primaryCompletion":674,"completion":674,"start":1195,"enrollment":1672,"conditions":1673,"interventions":1675},"NCT01773876","Empirical Antifungal Treatment in ICUS",[93],260,[1674],"Invasive Candidiasis",[1658],{"trials":1677,"activeCount":103},[],{"trials":1679,"activeCount":103},[],{"intervention":1681,"totalTrials":99,"cells":1682},"Islet Graft",{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1689,"PHASE4":1699,"NA":1701},{"trials":1684,"activeCount":103},[],{"trials":1686,"activeCount":103},[],{"trials":1688,"activeCount":103},[],{"trials":1690,"activeCount":103},[1691],{"nctId":1692,"briefTitle":1693,"status":401,"phases":1694,"primaryCompletion":1695,"completion":1129,"start":712,"enrollment":792,"conditions":1696,"interventions":1698},"NCT01148680","Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment",[93],"2018-08",[1697],"Diabetes Mellitus, Type 1",[1681],{"trials":1700,"activeCount":103},[],{"trials":1702,"activeCount":103},[],{"intervention":1276,"totalTrials":99,"cells":1704},{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1711,"PHASE4":1717,"NA":1719},{"trials":1706,"activeCount":103},[],{"trials":1708,"activeCount":103},[],{"trials":1710,"activeCount":103},[],{"trials":1712,"activeCount":103},[1713],{"nctId":1266,"briefTitle":1267,"status":401,"phases":1714,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":1715,"interventions":1716},[93],[1274],[1276,1246],{"trials":1718,"activeCount":103},[],{"trials":1720,"activeCount":103},[],{"intervention":1722,"totalTrials":99,"cells":1723},"Gelsemium Sempervirens",{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1730,"PHASE4":1742,"NA":1744},{"trials":1725,"activeCount":103},[],{"trials":1727,"activeCount":103},[],{"trials":1729,"activeCount":103},[],{"trials":1731,"activeCount":103},[1732],{"nctId":1733,"briefTitle":1734,"status":401,"phases":1735,"primaryCompletion":1736,"completion":1737,"start":1738,"enrollment":582,"conditions":1739,"interventions":1741},"NCT00914329","Gelsemium Sempervirens in Anticipatory Anxiety",[93],"2010-04","2010-05","2009-06",[1740],"Anxiety",[1722,1722],{"trials":1743,"activeCount":103},[],{"trials":1745,"activeCount":103},[],{"intervention":1747,"totalTrials":99,"cells":1748},"best medical care",{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1755,"PHASE4":1767,"NA":1769},{"trials":1750,"activeCount":103},[],{"trials":1752,"activeCount":103},[],{"trials":1754,"activeCount":103},[],{"trials":1756,"activeCount":103},[1757],{"nctId":1758,"briefTitle":1759,"status":919,"phases":1760,"primaryCompletion":1761,"completion":1234,"start":1762,"enrollment":1763,"conditions":1764,"interventions":1766},"NCT02854696","Health Economic Analysis of Islet Cell Transplantation for the Stabilization of the Severe Forms of Type 1 Diabetes",[93],"2023-05","2016-07-07",42,[1765],"Type 1 Diabetes",[1747],{"trials":1768,"activeCount":103},[],{"trials":1770,"activeCount":103},[],{"intervention":1772,"totalTrials":99,"cells":1773},"4th dose of hexavalent vaccine 1 month after the 3rd dose",{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1778,"PHASE3":1780,"PHASE4":1793,"NA":1795},{"trials":1775,"activeCount":103},[],{"trials":1777,"activeCount":103},[],{"trials":1779,"activeCount":103},[],{"trials":1781,"activeCount":103},[1782],{"nctId":1783,"briefTitle":1784,"status":919,"phases":1785,"primaryCompletion":1786,"completion":1787,"start":1788,"enrollment":1316,"conditions":1789,"interventions":1792},"NCT03402776","Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation",[93],"2020-05-31","2021-05-01","2018-05-01",[1790,1791],"Haemopoietic Stem Cell Transplantation","Allograft",[1772],{"trials":1794,"activeCount":103},[],{"trials":1796,"activeCount":103},[],{"intervention":1798,"totalTrials":99,"cells":1799},"methylphenidate",{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1806,"PHASE4":1818,"NA":1820},{"trials":1801,"activeCount":103},[],{"trials":1803,"activeCount":103},[],{"trials":1805,"activeCount":103},[],{"trials":1807,"activeCount":103},[1808],{"nctId":1809,"briefTitle":1810,"status":352,"phases":1811,"primaryCompletion":1738,"completion":1738,"start":1812,"enrollment":1813,"conditions":1814,"interventions":1817},"NCT00273741","Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients",[93],"2007-01",39,[1815,1816],"Asthenia","Neoplasms",[1798],{"trials":1819,"activeCount":103},[],{"trials":1821,"activeCount":103},[],{"intervention":1823,"totalTrials":99,"cells":1824},"Hydrocortisone",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1829,"PHASE3":1831,"PHASE4":1842,"NA":1844},{"trials":1826,"activeCount":103},[],{"trials":1828,"activeCount":103},[],{"trials":1830,"activeCount":103},[],{"trials":1832,"activeCount":103},[1833],{"nctId":1834,"briefTitle":1835,"status":401,"phases":1836,"primaryCompletion":1837,"completion":1837,"start":854,"enrollment":1838,"conditions":1839,"interventions":1841},"NCT00862381","Hydrocortisone Use After Etomidate in Intensive Care",[93],"2010-07",106,[1840],"Patient Admitted in Reanimation",[1823],{"trials":1843,"activeCount":103},[],{"trials":1845,"activeCount":103},[],{"intervention":1847,"totalTrials":99,"cells":1848},"lauromacrogol",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1855,"PHASE4":1867,"NA":1869},{"trials":1850,"activeCount":103},[],{"trials":1852,"activeCount":103},[],{"trials":1854,"activeCount":103},[],{"trials":1856,"activeCount":103},[1857],{"nctId":1858,"briefTitle":1859,"status":401,"phases":1860,"completion":991,"start":1861,"enrollment":1862,"conditions":1863,"interventions":1866},"NCT00348764","ESGVS: Sclerotherapy With Lauromacrogol",[93],"2004-03",150,[1864,1865],"Venous Insufficiency","Saphenous Vein",[1847],{"trials":1868,"activeCount":103},[],{"trials":1870,"activeCount":103},[],{"intervention":1872,"totalTrials":99,"cells":1873},"Usual treatment",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1893,"NA":1895},{"trials":1875,"activeCount":103},[],{"trials":1877,"activeCount":103},[],{"trials":1879,"activeCount":103},[],{"trials":1881,"activeCount":103},[1882],{"nctId":1883,"briefTitle":1884,"status":401,"phases":1885,"primaryCompletion":1886,"completion":1886,"start":1887,"enrollment":1888,"conditions":1889,"interventions":1892},"NCT02076698","Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy",[93],"2021-11-10","2014-06-16",62,[1890,1891],"Partial Epilepsy","Surgery",[1872],{"trials":1894,"activeCount":103},[],{"trials":1896,"activeCount":103},[],{"intervention":1898,"totalTrials":99,"cells":1899},"Rotigotine",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1906,"PHASE4":1918,"NA":1920},{"trials":1901,"activeCount":103},[],{"trials":1903,"activeCount":103},[],{"trials":1905,"activeCount":103},[],{"trials":1907,"activeCount":103},[1908],{"nctId":1909,"briefTitle":1910,"status":919,"phases":1911,"primaryCompletion":1912,"completion":1913,"start":711,"enrollment":1914,"conditions":1915,"interventions":1917},"NCT02786667","Non Motors Aspects in De Novo Parkinson's Disease",[93],"2017-10-15","2017-12",199,[15,1916],"Apathy",[1898],{"trials":1919,"activeCount":103},[],{"trials":1921,"activeCount":103},[],{"intervention":1923,"totalTrials":99,"cells":1924},"chemotherapy treatment (see arm) + norethandrolone",{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1931,"PHASE4":1946,"NA":1948},{"trials":1926,"activeCount":103},[],{"trials":1928,"activeCount":103},[],{"trials":1930,"activeCount":103},[],{"trials":1932,"activeCount":103},[1933],{"nctId":1934,"briefTitle":1935,"status":401,"phases":1936,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":1941,"interventions":1944},"NCT00700544","Treatment Outcome in Elderly Patients",[93],"2005-04","2008-05","2002-06",330,[1942,1943],"AML","Elderly Patients",[1923,1945],"chemotherapy treatment",{"trials":1947,"activeCount":103},[],{"trials":1949,"activeCount":103},[],{"intervention":1945,"totalTrials":99,"cells":1951},{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1958,"PHASE4":1964,"NA":1966},{"trials":1953,"activeCount":103},[],{"trials":1955,"activeCount":103},[],{"trials":1957,"activeCount":103},[],{"trials":1959,"activeCount":103},[1960],{"nctId":1934,"briefTitle":1935,"status":401,"phases":1961,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":1962,"interventions":1963},[93],[1942,1943],[1923,1945],{"trials":1965,"activeCount":103},[],{"trials":1967,"activeCount":103},[],{"intervention":1969,"totalTrials":99,"cells":1970},"intranasal fentanyl",{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1977,"PHASE4":1989,"NA":1991},{"trials":1972,"activeCount":103},[],{"trials":1974,"activeCount":103},[],{"trials":1976,"activeCount":103},[],{"trials":1978,"activeCount":103},[1979],{"nctId":1980,"briefTitle":1981,"status":401,"phases":1982,"primaryCompletion":1983,"completion":1128,"start":1984,"enrollment":1985,"conditions":1986,"interventions":1988},"NCT02298582","Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly",[92,93],"2017-10-24","2014-12-08",58,[1987],"Pain Due to Certain Specified Procedures",[1969],{"trials":1990,"activeCount":103},[],{"trials":1992,"activeCount":103},[],{"intervention":1994,"totalTrials":99,"cells":1995},"ketamine venlafaxine",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2014,"NA":2016},{"trials":1997,"activeCount":103},[],{"trials":1999,"activeCount":103},[],{"trials":2001,"activeCount":103},[],{"trials":2003,"activeCount":103},[2004],{"nctId":2005,"briefTitle":2006,"status":401,"phases":2007,"primaryCompletion":2008,"completion":2008,"start":2009,"enrollment":142,"conditions":2010,"interventions":2012},"NCT01557712","Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks",[93],"2017-01","2012-03",[2011],"Major Depressive Disorder",[1994,2013],"Venlafaxine",{"trials":2015,"activeCount":103},[],{"trials":2017,"activeCount":103},[],{"intervention":2013,"totalTrials":99,"cells":2019},{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2026,"PHASE4":2032,"NA":2034},{"trials":2021,"activeCount":103},[],{"trials":2023,"activeCount":103},[],{"trials":2025,"activeCount":103},[],{"trials":2027,"activeCount":103},[2028],{"nctId":2005,"briefTitle":2006,"status":401,"phases":2029,"primaryCompletion":2008,"completion":2008,"start":2009,"enrollment":142,"conditions":2030,"interventions":2031},[93],[2011],[1994,2013],{"trials":2033,"activeCount":103},[],{"trials":2035,"activeCount":103},[],{"intervention":718,"totalTrials":99,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2042,"PHASE3":2044,"PHASE4":2050,"NA":2052},{"trials":2039,"activeCount":103},[],{"trials":2041,"activeCount":103},[],{"trials":2043,"activeCount":103},[],{"trials":2045,"activeCount":103},[2046],{"nctId":708,"briefTitle":709,"status":401,"phases":2047,"primaryCompletion":711,"completion":711,"start":712,"enrollment":470,"conditions":2048,"interventions":2049},[93],[714,658,715,716],[718,694],{"trials":2051,"activeCount":103},[],{"trials":2053,"activeCount":103},[],{"intervention":2055,"totalTrials":99,"cells":2056},"Dexamethasone",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2075,"NA":2077},{"trials":2058,"activeCount":103},[],{"trials":2060,"activeCount":103},[],{"trials":2062,"activeCount":103},[],{"trials":2064,"activeCount":103},[2065],{"nctId":2066,"briefTitle":2067,"status":919,"phases":2068,"primaryCompletion":2069,"completion":2070,"start":2071,"enrollment":119,"conditions":2072,"interventions":2074},"NCT03084783","Dexamethasone in Herpes Simplex Virus Encephalitis",[93],"2020-11-01","2020-12-01","2018-11-01",[2073],"HSV Encephalitis",[2055],{"trials":2076,"activeCount":103},[],{"trials":2078,"activeCount":103},[],{"intervention":2080,"totalTrials":99,"cells":2081},"Atorvastatin treatment",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2096,"PHASE4":2098,"NA":2100},{"trials":2083,"activeCount":103},[],{"trials":2085,"activeCount":103},[],{"trials":2087,"activeCount":103},[2088],{"nctId":2089,"briefTitle":2090,"status":352,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":1938,"enrollment":2093,"conditions":2094,"interventions":2095},"NCT00669695","Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin",[92],"2013-02",54,[27],[2080],{"trials":2097,"activeCount":103},[],{"trials":2099,"activeCount":103},[],{"trials":2101,"activeCount":103},[],{"intervention":359,"totalTrials":99,"cells":2103},{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2114,"PHASE4":2116,"NA":2118},{"trials":2105,"activeCount":103},[],{"trials":2107,"activeCount":103},[],{"trials":2109,"activeCount":103},[2110],{"nctId":350,"briefTitle":351,"status":352,"phases":2111,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":2112,"interventions":2113},[92],[344],[359,331,346],{"trials":2115,"activeCount":103},[],{"trials":2117,"activeCount":103},[],{"trials":2119,"activeCount":103},[],{"intervention":2121,"totalTrials":99,"cells":2122},"Treprostinil iontophoresis",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2139,"PHASE4":2141,"NA":2143},{"trials":2124,"activeCount":103},[],{"trials":2126,"activeCount":103},[],{"trials":2128,"activeCount":103},[2129],{"nctId":2130,"briefTitle":2131,"status":352,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":2135,"conditions":2136,"interventions":2138},"NCT03654989","Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers",[91,92],"2021-12-07","2020-01-28",4,[2137],"Diabetic Foot Ulcer",[2121],{"trials":2140,"activeCount":103},[],{"trials":2142,"activeCount":103},[],{"trials":2144,"activeCount":103},[],{"intervention":2146,"totalTrials":99,"cells":2147},"Norepinephrine",{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2152,"PHASE3":2165,"PHASE4":2167,"NA":2169},{"trials":2149,"activeCount":103},[],{"trials":2151,"activeCount":103},[],{"trials":2153,"activeCount":103},[2154],{"nctId":2155,"briefTitle":2156,"status":919,"phases":2157,"primaryCompletion":2158,"completion":2159,"start":2160,"enrollment":16,"conditions":2161,"interventions":2163},"NCT02019810","Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury",[92],"2016-06","2016-10","2014-10",[2162],"Severe Traumatic Brain Injury With High Cerebral Pressure",[2146,2164],"Dobutamine and norepinephrine",{"trials":2166,"activeCount":103},[],{"trials":2168,"activeCount":103},[],{"trials":2170,"activeCount":103},[],{"intervention":2164,"totalTrials":99,"cells":2172},{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2183,"PHASE4":2185,"NA":2187},{"trials":2174,"activeCount":103},[],{"trials":2176,"activeCount":103},[],{"trials":2178,"activeCount":103},[2179],{"nctId":2155,"briefTitle":2156,"status":919,"phases":2180,"primaryCompletion":2158,"completion":2159,"start":2160,"enrollment":16,"conditions":2181,"interventions":2182},[92],[2162],[2146,2164],{"trials":2184,"activeCount":103},[],{"trials":2186,"activeCount":103},[],{"trials":2188,"activeCount":103},[],{"intervention":2190,"totalTrials":99,"cells":2191},"Lanreotide",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2193,"activeCount":103},[],{"trials":2195,"activeCount":103},[],{"trials":2197,"activeCount":103},[2198],{"nctId":2199,"briefTitle":2200,"status":401,"phases":2201,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":2204,"conditions":2205,"interventions":2207},"NCT02351128","Treatment of Unresecable and\u002For Metastatic Merkel Cell Carcinoma by Somatostatine Analogues",[92],"2017-05-15","2015-04",35,[2206],"Carcinoma, Merkel Cell",[2190],{"trials":2209,"activeCount":103},[],{"trials":2211,"activeCount":103},[],{"trials":2213,"activeCount":103},[],{"intervention":2215,"totalTrials":99,"cells":2216},"Cutaneous iontophoresis of treprostinil",{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2218,"activeCount":103},[],{"trials":2220,"activeCount":103},[],{"trials":2222,"activeCount":103},[2223],{"nctId":2224,"briefTitle":2225,"status":919,"phases":2226,"primaryCompletion":2227,"completion":2228,"start":2229,"enrollment":470,"conditions":2230,"interventions":2232},"NCT01554540","Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study",[91,92],"2013-10","2014-02","2012-02",[2231],"Scleroderma, Systemic",[2215],{"trials":2234,"activeCount":103},[],{"trials":2236,"activeCount":103},[],{"trials":2238,"activeCount":103},[],{"intervention":1261,"totalTrials":99,"cells":2240},{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2242,"activeCount":103},[],{"trials":2244,"activeCount":103},[],{"trials":2246,"activeCount":103},[2247],{"nctId":1255,"briefTitle":1256,"status":401,"phases":2248,"primaryCompletion":1194,"completion":1194,"start":1258,"enrollment":16,"conditions":2249,"interventions":2250},[91,92],[24],[1261,1262,1246],{"trials":2252,"activeCount":103},[],{"trials":2254,"activeCount":103},[],{"trials":2256,"activeCount":103},[],{"intervention":1262,"totalTrials":99,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2260,"activeCount":103},[],{"trials":2262,"activeCount":103},[],{"trials":2264,"activeCount":103},[2265],{"nctId":1255,"briefTitle":1256,"status":401,"phases":2266,"primaryCompletion":1194,"completion":1194,"start":1258,"enrollment":16,"conditions":2267,"interventions":2268},[91,92],[24],[1261,1262,1246],{"trials":2270,"activeCount":103},[],{"trials":2272,"activeCount":103},[],{"trials":2274,"activeCount":103},[],{"intervention":2276,"totalTrials":99,"cells":2277},"AGuIX®",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2296,"PHASE4":2298,"NA":2300},{"trials":2279,"activeCount":103},[],{"trials":2281,"activeCount":103},[],{"trials":2283,"activeCount":103},[2284],{"nctId":2285,"briefTitle":2286,"status":919,"phases":2287,"primaryCompletion":2288,"completion":2289,"start":2290,"enrollment":2291,"conditions":2292,"interventions":2295},"NCT03818386","Radiotherapy of Multiple Brain Metastases Using AGuIX®",[92],"2024-06-26","2025-03-26","2019-03-26",100,[2293,2294],"Brain Metastases, Adult","Radiotherapy",[2276],{"trials":2297,"activeCount":103},[],{"trials":2299,"activeCount":103},[],{"trials":2301,"activeCount":103},[],{"intervention":2303,"totalTrials":99,"cells":2304},"Deferasirox",{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2309,"PHASE3":2320,"PHASE4":2322,"NA":2324},{"trials":2306,"activeCount":103},[],{"trials":2308,"activeCount":103},[],{"trials":2310,"activeCount":103},[2311],{"nctId":2312,"briefTitle":2313,"status":401,"phases":2314,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":1813,"conditions":2317,"interventions":2319},"NCT03387475","Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents",[92],"2024-10-01","2018-02-20",[2318],"Myelodysplasia",[2303],{"trials":2321,"activeCount":103},[],{"trials":2323,"activeCount":103},[],{"trials":2325,"activeCount":103},[],{"intervention":2327,"totalTrials":99,"cells":2328},"Chemotherapy",{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2347,"PHASE4":2349,"NA":2351},{"trials":2330,"activeCount":103},[],{"trials":2332,"activeCount":103},[],{"trials":2334,"activeCount":103},[2335],{"nctId":2336,"briefTitle":2337,"status":352,"phases":2338,"primaryCompletion":2339,"completion":2340,"start":2341,"enrollment":2342,"conditions":2343,"interventions":2346},"NCT02806258","Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone",[91,92],"2024-05-16","2025-05-16","2016-04-26",362,[2344,2345],"Radiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation","Intermediate and High-risk Luminal and Triple Negative Breast Cancer",[2327],{"trials":2348,"activeCount":103},[],{"trials":2350,"activeCount":103},[],{"trials":2352,"activeCount":103},[],{"intervention":2354,"totalTrials":99,"cells":2355},"Evolocumab 140 MG\u002FML [Repatha]",{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2360,"PHASE3":2372,"PHASE4":2374,"NA":2376},{"trials":2357,"activeCount":103},[],{"trials":2359,"activeCount":103},[],{"trials":2361,"activeCount":103},[2362],{"nctId":2363,"briefTitle":2364,"status":919,"phases":2365,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":2368,"conditions":2369,"interventions":2371},"NCT04338165","Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography",[92],"2022-11","2021-01-08",66,[2370],"Atherosclerotic Cardiovascular Disease",[2354],{"trials":2373,"activeCount":103},[],{"trials":2375,"activeCount":103},[],{"trials":2377,"activeCount":103},[],{"intervention":2379,"totalTrials":99,"cells":2380},"epoetin beta",{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2385,"PHASE3":2397,"PHASE4":2399,"NA":2401},{"trials":2382,"activeCount":103},[],{"trials":2384,"activeCount":103},[],{"trials":2386,"activeCount":103},[2387],{"nctId":2388,"briefTitle":2389,"status":401,"phases":2390,"primaryCompletion":2391,"completion":2392,"start":2393,"enrollment":792,"conditions":2394,"interventions":2396},"NCT00273767","Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB",[92],"2009-07","2009-11","2006-01",[2395],"Myocardial Ischemia",[2379],{"trials":2398,"activeCount":103},[],{"trials":2400,"activeCount":103},[],{"trials":2402,"activeCount":103},[],{"intervention":2404,"totalTrials":99,"cells":2405},"Autologous mesenchymal stem cells",{"EARLY_PHASE1":2406,"PHASE1":2408,"PHASE2":2410,"PHASE3":2422,"PHASE4":2424,"NA":2426},{"trials":2407,"activeCount":103},[],{"trials":2409,"activeCount":103},[],{"trials":2411,"activeCount":103},[2412],{"nctId":2413,"briefTitle":2414,"status":401,"phases":2415,"primaryCompletion":2416,"completion":2416,"start":2417,"enrollment":2418,"conditions":2419,"interventions":2421},"NCT00875654","Intravenous Stem Cells After Ischemic Stroke",[92],"2017-10-20","2010-08",31,[2420,30],"Ischemia",[2404],{"trials":2423,"activeCount":103},[],{"trials":2425,"activeCount":103},[],{"trials":2427,"activeCount":103},[],{"intervention":2429,"totalTrials":99,"cells":2430},"Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2449,"PHASE4":2451,"NA":2453},{"trials":2432,"activeCount":103},[],{"trials":2434,"activeCount":103},[],{"trials":2436,"activeCount":103},[2437],{"nctId":2438,"briefTitle":2439,"status":352,"phases":2440,"primaryCompletion":2441,"completion":2442,"start":2443,"enrollment":2444,"conditions":2445,"interventions":2448},"NCT05145296","The Safety\u002FEfficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation",[92],"2024-12-01","2025-10-10","2022-01-19",5,[2446,2447],"Sensitisation","Highly Sensitised Dialysis Patients",[2429],{"trials":2450,"activeCount":103},[],{"trials":2452,"activeCount":103},[],{"trials":2454,"activeCount":103},[],{"intervention":2456,"totalTrials":99,"cells":2457},"Sandimmum",{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2475,"PHASE4":2477,"NA":2479},{"trials":2459,"activeCount":103},[],{"trials":2461,"activeCount":103},[],{"trials":2463,"activeCount":103},[2464],{"nctId":2465,"briefTitle":2466,"status":352,"phases":2467,"primaryCompletion":2468,"completion":2469,"start":2470,"enrollment":792,"conditions":2471,"interventions":2474},"NCT01002859","Effect of Preliminary Administration of Cyclosporine (Sandimmun ®) on Different Markers of Cardiac Ischaemia Induced by Cardiopulmonary Bypass",[92],"2011-05","2011-07","2009-04",[2472,2473],"Coronary Artery Bypass Surgery","Cardiopulmonary Bypass",[2456],{"trials":2476,"activeCount":103},[],{"trials":2478,"activeCount":103},[],{"trials":2480,"activeCount":103},[],{"intervention":2482,"totalTrials":99,"cells":2483},"Hypoxia, intermittent",{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2500,"PHASE4":2502,"NA":2504},{"trials":2485,"activeCount":103},[],{"trials":2487,"activeCount":103},[],{"trials":2489,"activeCount":103},[2490],{"nctId":2491,"briefTitle":2492,"status":2493,"phases":2494,"primaryCompletion":2495,"completion":2495,"start":2495,"enrollment":103,"conditions":2496,"interventions":2499},"NCT05210088","PLAsticity, Security and Tolerance to Intermittent Hypoxic Conditioning Following Stroke","WITHDRAWN",[91,92],"2024-01-01",[2497,2498],"Stroke, Ischemic","Stroke Sequelae",[2482],{"trials":2501,"activeCount":103},[],{"trials":2503,"activeCount":103},[],{"trials":2505,"activeCount":103},[],{"intervention":2507,"totalTrials":99,"cells":2508},"Iontophoresis of treprostinil",{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2524,"PHASE4":2526,"NA":2528},{"trials":2510,"activeCount":103},[],{"trials":2512,"activeCount":103},[],{"trials":2514,"activeCount":103},[2515],{"nctId":2516,"briefTitle":2517,"status":401,"phases":2518,"primaryCompletion":2519,"completion":2519,"start":2520,"enrollment":19,"conditions":2521,"interventions":2522},"NCT03120533","Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study",[91,92],"2019-06-03","2017-06-20",[2231],[2507,2523],"Iontophoresis of placebo",{"trials":2525,"activeCount":103},[],{"trials":2527,"activeCount":103},[],{"trials":2529,"activeCount":103},[],{"intervention":2523,"totalTrials":99,"cells":2531},{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2536,"PHASE3":2542,"PHASE4":2544,"NA":2546},{"trials":2533,"activeCount":103},[],{"trials":2535,"activeCount":103},[],{"trials":2537,"activeCount":103},[2538],{"nctId":2516,"briefTitle":2517,"status":401,"phases":2539,"primaryCompletion":2519,"completion":2519,"start":2520,"enrollment":19,"conditions":2540,"interventions":2541},[91,92],[2231],[2507,2523],{"trials":2543,"activeCount":103},[],{"trials":2545,"activeCount":103},[],{"trials":2547,"activeCount":103},[],{"intervention":2549,"totalTrials":99,"cells":2550},"Mixture 3,6% H2 in N2",{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2564,"PHASE3":2566,"PHASE4":2568,"NA":2570},{"trials":2552,"activeCount":103},[],{"trials":2554,"activeCount":103},[2555],{"nctId":2556,"briefTitle":2557,"status":401,"phases":2558,"primaryCompletion":2559,"completion":2560,"start":2070,"enrollment":28,"conditions":2561,"interventions":2563},"NCT04633980","Hydrogen Therapy in Patients With Moderate Covid-19",[91],"2022-06-30","2023-05-23",[2562],"Covid-19",[2549],{"trials":2565,"activeCount":103},[],{"trials":2567,"activeCount":103},[],{"trials":2569,"activeCount":103},[],{"trials":2571,"activeCount":103},[],{"intervention":2573,"totalTrials":99,"cells":2574},"C13 N15 Valine",{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2589,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2576,"activeCount":103},[],{"trials":2578,"activeCount":103},[2579],{"nctId":2580,"briefTitle":2581,"status":352,"phases":2582,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":2585,"conditions":2586,"interventions":2588},"NCT02305056","Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)",[91],"2018-01-30","2014-09",6,[2587],"High-grade Glioma",[2573],{"trials":2590,"activeCount":103},[],{"trials":2592,"activeCount":103},[],{"trials":2594,"activeCount":103},[],{"trials":2596,"activeCount":103},[],{"intervention":2598,"totalTrials":99,"cells":2599},"AGuIX",{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2612,"PHASE3":2614,"PHASE4":2616,"NA":2618},{"trials":2601,"activeCount":103},[],{"trials":2603,"activeCount":103},[2604],{"nctId":2605,"briefTitle":2606,"status":401,"phases":2607,"primaryCompletion":2608,"completion":2608,"start":1153,"enrollment":25,"conditions":2609,"interventions":2611},"NCT02820454","Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles",[91],"2019-02",[2610],"Brain Metastases",[2598],{"trials":2613,"activeCount":103},[],{"trials":2615,"activeCount":103},[],{"trials":2617,"activeCount":103},[],{"trials":2619,"activeCount":103},[],{"intervention":409,"totalTrials":99,"cells":2621},{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2630,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2623,"activeCount":103},[],{"trials":2625,"activeCount":103},[2626],{"nctId":399,"briefTitle":400,"status":401,"phases":2627,"primaryCompletion":403,"completion":404,"start":405,"enrollment":342,"conditions":2628,"interventions":2629},[91],[407],[68,409,410,411,412],{"trials":2631,"activeCount":103},[],{"trials":2633,"activeCount":103},[],{"trials":2635,"activeCount":103},[],{"trials":2637,"activeCount":103},[],{"intervention":410,"totalTrials":99,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2648,"PHASE3":2650,"PHASE4":2652,"NA":2654},{"trials":2641,"activeCount":103},[],{"trials":2643,"activeCount":103},[2644],{"nctId":399,"briefTitle":400,"status":401,"phases":2645,"primaryCompletion":403,"completion":404,"start":405,"enrollment":342,"conditions":2646,"interventions":2647},[91],[407],[68,409,410,411,412],{"trials":2649,"activeCount":103},[],{"trials":2651,"activeCount":103},[],{"trials":2653,"activeCount":103},[],{"trials":2655,"activeCount":103},[],{"intervention":411,"totalTrials":99,"cells":2657},{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2666,"PHASE3":2668,"PHASE4":2670,"NA":2672},{"trials":2659,"activeCount":103},[],{"trials":2661,"activeCount":103},[2662],{"nctId":399,"briefTitle":400,"status":401,"phases":2663,"primaryCompletion":403,"completion":404,"start":405,"enrollment":342,"conditions":2664,"interventions":2665},[91],[407],[68,409,410,411,412],{"trials":2667,"activeCount":103},[],{"trials":2669,"activeCount":103},[],{"trials":2671,"activeCount":103},[],{"trials":2673,"activeCount":103},[],{"intervention":412,"totalTrials":99,"cells":2675},{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2684,"PHASE3":2686,"PHASE4":2688,"NA":2690},{"trials":2677,"activeCount":103},[],{"trials":2679,"activeCount":103},[2680],{"nctId":399,"briefTitle":400,"status":401,"phases":2681,"primaryCompletion":403,"completion":404,"start":405,"enrollment":342,"conditions":2682,"interventions":2683},[91],[407],[68,409,410,411,412],{"trials":2685,"activeCount":103},[],{"trials":2687,"activeCount":103},[],{"trials":2689,"activeCount":103},[],{"trials":2691,"activeCount":103},[],{"intervention":2693,"totalTrials":99,"cells":2694},"99mTccAbVCAM1-5",{"EARLY_PHASE1":2695,"PHASE1":2697,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2696,"activeCount":103},[],{"trials":2698,"activeCount":103},[2699],{"nctId":2700,"briefTitle":2701,"status":919,"phases":2702,"primaryCompletion":1761,"completion":1761,"start":2703,"enrollment":2704,"conditions":2705,"interventions":2708},"NCT04483167","Clinical Transfer of a Vulnerable Atherosclerotic Plaque Tracer : 99mTc-cAbVCAM1-5 (ATHENA)",[91],"2020-09-15",13,[2706,2707],"Cardiovascular Diseases","Atherosclerosis",[2693],{"trials":2710,"activeCount":103},[],{"trials":2712,"activeCount":103},[],{"trials":2714,"activeCount":103},[],{"trials":2716,"activeCount":103},[],{"intervention":2718,"totalTrials":99,"cells":2719},"GeniusVac-Mel4",{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2735,"PHASE3":2737,"PHASE4":2739,"NA":2741},{"trials":2721,"activeCount":103},[],{"trials":2723,"activeCount":103},[2724],{"nctId":2725,"briefTitle":2726,"status":401,"phases":2727,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":37,"conditions":2730,"interventions":2734},"NCT01863108","Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma",[91],"2017-03-23","2013-06",[2731,2732,2733],"Melanoma","Tumor Vaccines","Effects of Immunotherapy",[2718],{"trials":2736,"activeCount":103},[],{"trials":2738,"activeCount":103},[],{"trials":2740,"activeCount":103},[],{"trials":2742,"activeCount":103},[],{"intervention":2744,"totalTrials":332,"cells":2745},"Blood Sampling",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2752,"PHASE4":2754,"NA":2756},{"trials":2747,"activeCount":103},[],{"trials":2749,"activeCount":103},[],{"trials":2751,"activeCount":103},[],{"trials":2753,"activeCount":103},[],{"trials":2755,"activeCount":103},[],{"trials":2757,"activeCount":103},[2758,2771],{"nctId":2759,"briefTitle":2760,"status":919,"phases":2761,"primaryCompletion":2762,"completion":2763,"start":2764,"enrollment":2765,"conditions":2766,"interventions":2769},"NCT03753308","Mechanism of DCs Dysfunction in Chronic HBV Infection",[],"2021-12-05","2022-12-31","2018-12-05",132,[2767,2768],"HBV","NASH - Nonalcoholic Steatohepatitis",[2744,2770],"Liver biopsy",{"nctId":2772,"briefTitle":2773,"status":352,"phases":2774,"primaryCompletion":2158,"completion":2775,"start":2776,"enrollment":2777,"conditions":2778,"interventions":2780},"NCT02841358","Screening of Niemann-Pick Disease, Type C in a Psychiatric Population",[95],"2016-12","2013-12",22,[2779],"Psychiatric Adults Patients",[2781,2782],"Blood sampling","Biopsy",{"intervention":2784,"totalTrials":99,"cells":2785},"ProteoCIT®",{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2790,"PHASE3":2792,"PHASE4":2794,"NA":2796},{"trials":2787,"activeCount":103},[],{"trials":2789,"activeCount":103},[],{"trials":2791,"activeCount":103},[],{"trials":2793,"activeCount":103},[],{"trials":2795,"activeCount":103},[],{"trials":2797,"activeCount":103},[2798],{"nctId":2799,"briefTitle":2800,"status":919,"phases":2801,"primaryCompletion":2802,"completion":2803,"start":2802,"enrollment":205,"conditions":2804,"interventions":2806},"NCT03694964","Severe Chronic Respiratory Failure and Citrulline",[95],"2019-01","2021-07",[2805],"Pulmonary Disease, Chronic Obstructive",[2784],{"intervention":2808,"totalTrials":99,"cells":2809},"Immunomonitoring",{"EARLY_PHASE1":2810,"PHASE1":2812,"PHASE2":2814,"PHASE3":2816,"PHASE4":2818,"NA":2820},{"trials":2811,"activeCount":103},[],{"trials":2813,"activeCount":103},[],{"trials":2815,"activeCount":103},[],{"trials":2817,"activeCount":103},[],{"trials":2819,"activeCount":103},[],{"trials":2821,"activeCount":103},[2822],{"nctId":2823,"briefTitle":2824,"status":919,"phases":2825,"primaryCompletion":2826,"completion":2827,"start":2828,"enrollment":2829,"conditions":2830,"interventions":2832},"NCT04645849","Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer",[],"2021-08","2021-11","2020-06-15",26,[2831],"Breast Cancer",[2808],{"intervention":2834,"totalTrials":99,"cells":2835},"Meta-genomic signature of intestinal flora",{"EARLY_PHASE1":2836,"PHASE1":2838,"PHASE2":2840,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2837,"activeCount":103},[],{"trials":2839,"activeCount":103},[],{"trials":2841,"activeCount":103},[],{"trials":2843,"activeCount":103},[],{"trials":2845,"activeCount":103},[],{"trials":2847,"activeCount":103},[2848],{"nctId":2849,"briefTitle":2850,"status":401,"phases":2851,"primaryCompletion":2852,"completion":2852,"start":2853,"enrollment":1888,"conditions":2854,"interventions":2856},"NCT04189679","Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma",[],"2023-01-27","2020-01-03",[2855],"Non Small Cell Lung Cancer",[2834],{"intervention":2858,"totalTrials":99,"cells":2859},"L-NMMA and Fluconazole dermic",{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2864,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2861,"activeCount":103},[],{"trials":2863,"activeCount":103},[],{"trials":2865,"activeCount":103},[],{"trials":2867,"activeCount":103},[],{"trials":2869,"activeCount":103},[],{"trials":2871,"activeCount":103},[2872],{"nctId":2873,"briefTitle":2874,"status":919,"phases":2875,"primaryCompletion":2159,"completion":2876,"start":2877,"enrollment":205,"conditions":2878,"interventions":2882},"NCT02183779","PORH and Response to Cold in Raynaud's Phenomenon.",[95],"2017-06","2014-06",[2879,2880,2881],"Raynaud Disease","Hyperemia","Cold",[2858],{"intervention":2884,"totalTrials":99,"cells":2885},"remifentanil",{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2892,"PHASE4":2894,"NA":2896},{"trials":2887,"activeCount":103},[],{"trials":2889,"activeCount":103},[],{"trials":2891,"activeCount":103},[],{"trials":2893,"activeCount":103},[],{"trials":2895,"activeCount":103},[],{"trials":2897,"activeCount":103},[2898],{"nctId":2899,"briefTitle":2900,"status":401,"phases":2901,"primaryCompletion":2902,"completion":2902,"start":2470,"enrollment":22,"conditions":2903,"interventions":2905},"NCT01015651","Assessment of the Nociception During Lumbar Surgery",[95],"2009-10",[2904],"Lumbar Surgery",[2884,2884],{"intervention":2907,"totalTrials":99,"cells":2908},"Microdialysis of fluconazole, vehicle and N",{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2915,"PHASE4":2917,"NA":2919},{"trials":2910,"activeCount":103},[],{"trials":2912,"activeCount":103},[],{"trials":2914,"activeCount":103},[],{"trials":2916,"activeCount":103},[],{"trials":2918,"activeCount":103},[],{"trials":2920,"activeCount":103},[2921],{"nctId":2922,"briefTitle":2923,"status":401,"phases":2924,"primaryCompletion":2925,"completion":2926,"start":2927,"enrollment":16,"conditions":2928,"interventions":2929},"NCT01290198","Role of Epoxy-eicosatrienoic Acids in Post-occlusive Hyperemia and Thermal Hyperemia",[95],"2012-04","2012-05","2011-02",[21],[2907],{"intervention":2931,"totalTrials":99,"cells":2932},"immunosuppressor\u002FTNFalpha",{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2937,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2934,"activeCount":103},[],{"trials":2936,"activeCount":103},[],{"trials":2938,"activeCount":103},[],{"trials":2940,"activeCount":103},[],{"trials":2942,"activeCount":103},[],{"trials":2944,"activeCount":103},[2945],{"nctId":2946,"briefTitle":2947,"status":919,"phases":2948,"primaryCompletion":2949,"completion":2950,"start":2951,"enrollment":470,"conditions":2952,"interventions":2954},"NCT03623932","Contribution of a Non Medicamentous Approach by Hypnosis on Quality of Life in Crohn Disease",[95],"2021-11-12","2021-11-13","2018-11-13",[2953],"Crohn Disease",[2931],{"intervention":2956,"totalTrials":99,"cells":2957},"Evaluation of post-ischemic vascular reactivity",{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2964,"PHASE4":2966,"NA":2968},{"trials":2959,"activeCount":103},[],{"trials":2961,"activeCount":103},[],{"trials":2963,"activeCount":103},[],{"trials":2965,"activeCount":103},[],{"trials":2967,"activeCount":103},[],{"trials":2969,"activeCount":103},[2970],{"nctId":2971,"briefTitle":2972,"status":401,"phases":2973,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":2976,"conditions":2977,"interventions":2979},"NCT02850367","Effect of NO Precursors on Physiological Responses to Exercise",[95],"2021-09","2016-05-09",63,[2978],"Physiology",[2956,2980],"Neuromuscular evaluations",{"intervention":2980,"totalTrials":99,"cells":2982},{"EARLY_PHASE1":2983,"PHASE1":2985,"PHASE2":2987,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2984,"activeCount":103},[],{"trials":2986,"activeCount":103},[],{"trials":2988,"activeCount":103},[],{"trials":2990,"activeCount":103},[],{"trials":2992,"activeCount":103},[],{"trials":2994,"activeCount":103},[2995],{"nctId":2971,"briefTitle":2972,"status":401,"phases":2996,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":2976,"conditions":2997,"interventions":2998},[95],[2978],[2956,2980],{"intervention":3000,"totalTrials":99,"cells":3001},"2% CHX cloths",{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3008,"PHASE4":3010,"NA":3012},{"trials":3003,"activeCount":103},[],{"trials":3005,"activeCount":103},[],{"trials":3007,"activeCount":103},[],{"trials":3009,"activeCount":103},[],{"trials":3011,"activeCount":103},[],{"trials":3013,"activeCount":103},[3014],{"nctId":3015,"briefTitle":3016,"status":401,"phases":3017,"primaryCompletion":3018,"completion":3018,"start":3019,"enrollment":3020,"conditions":3021,"interventions":3023},"NCT05120739","Efficacy of CHX Cloths Versus CHX Soaps for Bathes Before Orthopedic Surgery",[95],"2023-05-30","2021-11-15",64,[3022],"Orthopedic Surgery",[3000],{"intervention":3025,"totalTrials":99,"cells":3026},"Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition",{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3031,"PHASE3":3033,"PHASE4":3035,"NA":3037},{"trials":3028,"activeCount":103},[],{"trials":3030,"activeCount":103},[],{"trials":3032,"activeCount":103},[],{"trials":3034,"activeCount":103},[],{"trials":3036,"activeCount":103},[],{"trials":3038,"activeCount":103},[3039],{"nctId":3040,"briefTitle":3041,"status":352,"phases":3042,"primaryCompletion":2160,"start":3043,"enrollment":3044,"conditions":3045,"interventions":3047},"NCT01716403","Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy",[],"2012-10",8,[3046],"C Hepatitis, Tri Therapy",[3025],{"intervention":3049,"totalTrials":99,"cells":3050},"Mepolizumab",{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3052,"activeCount":103},[],{"trials":3054,"activeCount":103},[],{"trials":3056,"activeCount":103},[],{"trials":3058,"activeCount":103},[],{"trials":3060,"activeCount":103},[],{"trials":3062,"activeCount":103},[3063],{"nctId":3064,"briefTitle":3065,"status":401,"phases":3066,"primaryCompletion":3067,"completion":3067,"start":3068,"enrollment":3069,"conditions":3070,"interventions":3072},"NCT03453021","Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma",[],"2017-10-31","2016-01-25",27,[3071],"Asthma; Eosinophilic",[3049],{"intervention":2770,"totalTrials":99,"cells":3074},{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3079,"PHASE3":3081,"PHASE4":3083,"NA":3085},{"trials":3076,"activeCount":103},[],{"trials":3078,"activeCount":103},[],{"trials":3080,"activeCount":103},[],{"trials":3082,"activeCount":103},[],{"trials":3084,"activeCount":103},[],{"trials":3086,"activeCount":103},[3087],{"nctId":2759,"briefTitle":2760,"status":919,"phases":3088,"primaryCompletion":2762,"completion":2763,"start":2764,"enrollment":2765,"conditions":3089,"interventions":3090},[],[2767,2768],[2744,2770],{"intervention":3092,"totalTrials":99,"cells":3093},"visits of tocilizumab",{"EARLY_PHASE1":3094,"PHASE1":3096,"PHASE2":3098,"PHASE3":3100,"PHASE4":3102,"NA":3104},{"trials":3095,"activeCount":103},[],{"trials":3097,"activeCount":103},[],{"trials":3099,"activeCount":103},[],{"trials":3101,"activeCount":103},[],{"trials":3103,"activeCount":103},[],{"trials":3105,"activeCount":103},[3106],{"nctId":3107,"briefTitle":3108,"status":352,"phases":3109,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":3044,"conditions":3112,"interventions":3116},"NCT03507348","Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates",[95],"2019-11-21","2018-07-01",[3113,3114,3115],"End-stage Renal Disease","Kidney Transplantation","Hla-incompatible Kidney Transplant Candidates",[3092,3117,3118],"Rituximab 375 mg\u002Fm2 at Day-30","Rituximab 375 mg\u002Fm2 at Day-15",{"intervention":3117,"totalTrials":99,"cells":3120},{"EARLY_PHASE1":3121,"PHASE1":3123,"PHASE2":3125,"PHASE3":3127,"PHASE4":3129,"NA":3131},{"trials":3122,"activeCount":103},[],{"trials":3124,"activeCount":103},[],{"trials":3126,"activeCount":103},[],{"trials":3128,"activeCount":103},[],{"trials":3130,"activeCount":103},[],{"trials":3132,"activeCount":103},[3133],{"nctId":3107,"briefTitle":3108,"status":352,"phases":3134,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":3044,"conditions":3135,"interventions":3136},[95],[3113,3114,3115],[3092,3117,3118],{"intervention":3118,"totalTrials":99,"cells":3138},{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3140,"activeCount":103},[],{"trials":3142,"activeCount":103},[],{"trials":3144,"activeCount":103},[],{"trials":3146,"activeCount":103},[],{"trials":3148,"activeCount":103},[],{"trials":3150,"activeCount":103},[3151],{"nctId":3107,"briefTitle":3108,"status":352,"phases":3152,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":3044,"conditions":3153,"interventions":3154},[95],[3113,3114,3115],[3092,3117,3118],{"intervention":3156,"totalTrials":99,"cells":3157},"Adalimumab",{"EARLY_PHASE1":3158,"PHASE1":3160,"PHASE2":3162,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3159,"activeCount":103},[],{"trials":3161,"activeCount":103},[],{"trials":3163,"activeCount":103},[],{"trials":3165,"activeCount":103},[],{"trials":3167,"activeCount":103},[],{"trials":3169,"activeCount":103},[3170],{"nctId":3171,"briefTitle":3172,"status":401,"phases":3173,"primaryCompletion":3174,"completion":3175,"start":3176,"enrollment":792,"conditions":3177,"interventions":3179},"NCT03561649","Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA",[95],"2019-12-14","2020-05-07","2018-06-14",[3178],"Spondylitis, Ankylosing",[3156],{"intervention":3181,"totalTrials":99,"cells":3182},"Pedalling exercise on a cycle ergometer",{"EARLY_PHASE1":3183,"PHASE1":3185,"PHASE2":3187,"PHASE3":3189,"PHASE4":3191,"NA":3193},{"trials":3184,"activeCount":103},[],{"trials":3186,"activeCount":103},[],{"trials":3188,"activeCount":103},[],{"trials":3190,"activeCount":103},[],{"trials":3192,"activeCount":103},[],{"trials":3194,"activeCount":103},[3195],{"nctId":3196,"briefTitle":3197,"status":401,"phases":3198,"primaryCompletion":1130,"completion":3199,"start":2729,"enrollment":3200,"conditions":3201,"interventions":3204},"NCT02854280","Brain During Effort : Effects of Hypoxia With Respiratory Patients",[95],"2018-03",33,[3202,3203,21],"Chronic Obstructive Pulmonary Disease (COPD)","Sleep Apnea Obstructive (OSA)",[3181,3205],"Isolated contractions of the quadriceps",{"intervention":3205,"totalTrials":99,"cells":3207},{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3214,"PHASE4":3216,"NA":3218},{"trials":3209,"activeCount":103},[],{"trials":3211,"activeCount":103},[],{"trials":3213,"activeCount":103},[],{"trials":3215,"activeCount":103},[],{"trials":3217,"activeCount":103},[],{"trials":3219,"activeCount":103},[3220],{"nctId":3196,"briefTitle":3197,"status":401,"phases":3221,"primaryCompletion":1130,"completion":3199,"start":2729,"enrollment":3200,"conditions":3222,"interventions":3223},[95],[3202,3203,21],[3181,3205],{"intervention":3225,"totalTrials":99,"cells":3226},"Dosage of biomarkers",{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3231,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3228,"activeCount":103},[],{"trials":3230,"activeCount":103},[],{"trials":3232,"activeCount":103},[],{"trials":3234,"activeCount":103},[],{"trials":3236,"activeCount":103},[],{"trials":3238,"activeCount":103},[3239],{"nctId":3240,"briefTitle":3241,"status":352,"phases":3242,"primaryCompletion":3243,"completion":3243,"start":3244,"enrollment":2291,"conditions":3245,"interventions":3247},"NCT02844023","Biomarkers in Giant Cells Arteritis",[95],"2019-01-14","2015-01",[3246],"Giant Cells Arteritis",[3225],{"intervention":2782,"totalTrials":99,"cells":3249},{"EARLY_PHASE1":3250,"PHASE1":3252,"PHASE2":3254,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3251,"activeCount":103},[],{"trials":3253,"activeCount":103},[],{"trials":3255,"activeCount":103},[],{"trials":3257,"activeCount":103},[],{"trials":3259,"activeCount":103},[],{"trials":3261,"activeCount":103},[3262],{"nctId":2772,"briefTitle":2773,"status":352,"phases":3263,"primaryCompletion":2158,"completion":2775,"start":2776,"enrollment":2777,"conditions":3264,"interventions":3265},[95],[2779],[2781,2782],{"intervention":3267,"totalTrials":99,"cells":3268},"Endophenotype and sequencing",{"EARLY_PHASE1":3269,"PHASE1":3271,"PHASE2":3273,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3270,"activeCount":103},[],{"trials":3272,"activeCount":103},[],{"trials":3274,"activeCount":103},[],{"trials":3276,"activeCount":103},[],{"trials":3278,"activeCount":103},[],{"trials":3280,"activeCount":103},[3281],{"nctId":3282,"briefTitle":3283,"status":919,"phases":3284,"primaryCompletion":454,"completion":454,"start":674,"enrollment":3285,"conditions":3286,"interventions":3287},"NCT02843997","Endophenotype Characterization of a Family Psychiatric Disorder",[95],29,[33],[3267],{"intervention":3289,"totalTrials":99,"cells":3290},"Patient Current Care",{"EARLY_PHASE1":3291,"PHASE1":3293,"PHASE2":3295,"PHASE3":3297,"PHASE4":3299,"NA":3301},{"trials":3292,"activeCount":103},[],{"trials":3294,"activeCount":103},[],{"trials":3296,"activeCount":103},[],{"trials":3298,"activeCount":103},[],{"trials":3300,"activeCount":103},[],{"trials":3302,"activeCount":103},[3303],{"nctId":3304,"briefTitle":3305,"status":2493,"phases":3306,"primaryCompletion":3307,"completion":3308,"start":3309,"enrollment":103,"conditions":3310,"interventions":3313},"NCT04117165","Assessment of the Clinical and Medico-economic Impact of SinnoTest® in Patients With Rheumatoid Arthritis",[95],"2022-09-01","2023-09-01","2021-03-01",[3311,3312],"Arthritis, Rheumatoid","Biological Therapy",[3289],{"intervention":3315,"totalTrials":99,"cells":3316},"CK2 and ATM inhibitors serine\u002F threonin Kinase combination",{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3318,"activeCount":103},[],{"trials":3320,"activeCount":103},[],{"trials":3322,"activeCount":103},[],{"trials":3324,"activeCount":103},[],{"trials":3326,"activeCount":103},[],{"trials":3328,"activeCount":103},[3329],{"nctId":3330,"briefTitle":3331,"status":919,"phases":3332,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":2291,"conditions":3336,"interventions":3338},"NCT03571438","Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors",[95],"2022-09-30","2024-09-30","2017-10-16",[3337],"Kidney Cancer",[3315,3339,3340,3341],"Sunitinib","Pazopanib","Temsirolimus",{"intervention":3339,"totalTrials":99,"cells":3343},{"EARLY_PHASE1":3344,"PHASE1":3346,"PHASE2":3348,"PHASE3":3350,"PHASE4":3352,"NA":3354},{"trials":3345,"activeCount":103},[],{"trials":3347,"activeCount":103},[],{"trials":3349,"activeCount":103},[],{"trials":3351,"activeCount":103},[],{"trials":3353,"activeCount":103},[],{"trials":3355,"activeCount":103},[3356],{"nctId":3330,"briefTitle":3331,"status":919,"phases":3357,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":2291,"conditions":3358,"interventions":3359},[95],[3337],[3315,3339,3340,3341],{"intervention":3340,"totalTrials":99,"cells":3361},{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3368,"PHASE4":3370,"NA":3372},{"trials":3363,"activeCount":103},[],{"trials":3365,"activeCount":103},[],{"trials":3367,"activeCount":103},[],{"trials":3369,"activeCount":103},[],{"trials":3371,"activeCount":103},[],{"trials":3373,"activeCount":103},[3374],{"nctId":3330,"briefTitle":3331,"status":919,"phases":3375,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":2291,"conditions":3376,"interventions":3377},[95],[3337],[3315,3339,3340,3341],{"intervention":3341,"totalTrials":99,"cells":3379},{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3386,"PHASE4":3388,"NA":3390},{"trials":3381,"activeCount":103},[],{"trials":3383,"activeCount":103},[],{"trials":3385,"activeCount":103},[],{"trials":3387,"activeCount":103},[],{"trials":3389,"activeCount":103},[],{"trials":3391,"activeCount":103},[3392],{"nctId":3330,"briefTitle":3331,"status":919,"phases":3393,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":2291,"conditions":3394,"interventions":3395},[95],[3337],[3315,3339,3340,3341],{"intervention":3397,"totalTrials":99,"cells":3398},"Botulinum Toxin",{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3405,"PHASE4":3407,"NA":3409},{"trials":3400,"activeCount":103},[],{"trials":3402,"activeCount":103},[],{"trials":3404,"activeCount":103},[],{"trials":3406,"activeCount":103},[],{"trials":3408,"activeCount":103},[],{"trials":3410,"activeCount":103},[3411],{"nctId":3412,"briefTitle":3413,"status":401,"phases":3414,"primaryCompletion":3415,"completion":3415,"start":3416,"enrollment":470,"conditions":3417,"interventions":3420},"NCT03938363","Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia",[95],"2022-06-13","2019-10-23",[3418,3419],"Cervical Dystonia, Primary","Blepharospasm",[3397],{"intervention":3422,"totalTrials":99,"cells":3423},"Characterization of early biological effects following exposure to PAHs",{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3428,"PHASE3":3430,"PHASE4":3432,"NA":3434},{"trials":3425,"activeCount":103},[],{"trials":3427,"activeCount":103},[],{"trials":3429,"activeCount":103},[],{"trials":3431,"activeCount":103},[],{"trials":3433,"activeCount":103},[],{"trials":3435,"activeCount":103},[3436],{"nctId":3437,"briefTitle":3438,"status":919,"phases":3439,"primaryCompletion":57,"completion":57,"start":3440,"enrollment":2291,"conditions":3441,"interventions":3445},"NCT05679544","Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs",[95],"2023-04-25",[3442,3443,3444],"Metabolic Disturbance","Protein Deficiency","Genotoxicity",[3422],{"intervention":3447,"totalTrials":99,"cells":3448},"PCR : 16S ribosomal DNA and real-time targeted PCR",{"EARLY_PHASE1":3449,"PHASE1":3451,"PHASE2":3453,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3450,"activeCount":103},[],{"trials":3452,"activeCount":103},[],{"trials":3454,"activeCount":103},[],{"trials":3456,"activeCount":103},[],{"trials":3458,"activeCount":103},[],{"trials":3460,"activeCount":103},[3461],{"nctId":3462,"briefTitle":3463,"status":919,"phases":3464,"primaryCompletion":1497,"completion":1497,"start":3465,"enrollment":1862,"conditions":3466,"interventions":3468},"NCT02850653","Targeted PCR and Acute Endophthalmitis",[95],"2007-11",[3467],"Acute Endophthalmitis Post-operative",[3447,3469],"Sampling of aqueous humour",{"intervention":3469,"totalTrials":99,"cells":3471},{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3478,"PHASE4":3480,"NA":3482},{"trials":3473,"activeCount":103},[],{"trials":3475,"activeCount":103},[],{"trials":3477,"activeCount":103},[],{"trials":3479,"activeCount":103},[],{"trials":3481,"activeCount":103},[],{"trials":3483,"activeCount":103},[3484],{"nctId":3462,"briefTitle":3463,"status":919,"phases":3485,"primaryCompletion":1497,"completion":1497,"start":3465,"enrollment":1862,"conditions":3486,"interventions":3487},[95],[3467],[3447,3469],{"intervention":3489,"totalTrials":99,"cells":3490},"bronchial mucus collection",{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3495,"PHASE3":3497,"PHASE4":3499,"NA":3501},{"trials":3492,"activeCount":103},[],{"trials":3494,"activeCount":103},[],{"trials":3496,"activeCount":103},[],{"trials":3498,"activeCount":103},[],{"trials":3500,"activeCount":103},[],{"trials":3502,"activeCount":103},[3503],{"nctId":3504,"briefTitle":3505,"status":919,"phases":3506,"primaryCompletion":3507,"completion":1234,"start":3508,"enrollment":2291,"conditions":3509,"interventions":3511},"NCT04687319","RHEology of the Pulmonary MUcus",[],"2023-01","2021-01",[3510],"Bronchial Mucus in COPD and Cystic Fibrosis",[3489],{"intervention":3513,"totalTrials":99,"cells":3514},"Diagnostic",{"EARLY_PHASE1":3515,"PHASE1":3517,"PHASE2":3519,"PHASE3":3521,"PHASE4":3523,"NA":3525},{"trials":3516,"activeCount":103},[],{"trials":3518,"activeCount":103},[],{"trials":3520,"activeCount":103},[],{"trials":3522,"activeCount":103},[],{"trials":3524,"activeCount":103},[],{"trials":3526,"activeCount":103},[3527],{"nctId":3528,"briefTitle":3529,"status":401,"phases":3530,"primaryCompletion":1015,"completion":3531,"start":1236,"enrollment":3532,"conditions":3533,"interventions":3535},"NCT02872948","Diagnosis Accuracy of Noninvasive Screening by PCR Digital for Down Syndrom",[],"2017-07",1260,[3534],"Trisomy 21",[3513],{"intervention":3537,"totalTrials":99,"cells":3538},"Real-time PCR testing of lower respiratory tract samples",{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3547,"NA":3549},{"trials":3540,"activeCount":103},[],{"trials":3542,"activeCount":103},[],{"trials":3544,"activeCount":103},[],{"trials":3546,"activeCount":103},[],{"trials":3548,"activeCount":103},[],{"trials":3550,"activeCount":103},[3551],{"nctId":3552,"briefTitle":3553,"status":401,"phases":3554,"primaryCompletion":3555,"completion":3556,"start":3557,"enrollment":3558,"conditions":3559,"interventions":3561},"NCT02884700","Severe Legionellosis Cases Admitted to Grenoble University Hospital, 2006-2011.",[],"2011-12","2014-12","2009-09",82,[3560],"Legionnaires' Disease",[3537],{"intervention":3563,"totalTrials":99,"cells":3564},"Biological examinations (blood and urinary).",{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3569,"PHASE3":3571,"PHASE4":3573,"NA":3575},{"trials":3566,"activeCount":103},[],{"trials":3568,"activeCount":103},[],{"trials":3570,"activeCount":103},[],{"trials":3572,"activeCount":103},[],{"trials":3574,"activeCount":103},[],{"trials":3576,"activeCount":103},[3577],{"nctId":3578,"briefTitle":3579,"status":352,"phases":3580,"primaryCompletion":1223,"completion":1223,"start":3581,"enrollment":11,"conditions":3582,"interventions":3583},"NCT00805974","Study of the Relationship Between Sleep Quality and Daytime-Nighttime Variations of Blood Pressure and Plasma Glucose Type I",[95],"2005-10",[1765],[3563],{"intervention":3585,"totalTrials":99,"cells":3586},"Etanercept ® 50 mg",{"EARLY_PHASE1":3587,"PHASE1":3589,"PHASE2":3591,"PHASE3":3593,"PHASE4":3595,"NA":3597},{"trials":3588,"activeCount":103},[],{"trials":3590,"activeCount":103},[],{"trials":3592,"activeCount":103},[],{"trials":3594,"activeCount":103},[],{"trials":3596,"activeCount":103},[],{"trials":3598,"activeCount":103},[3599],{"nctId":3600,"briefTitle":3601,"status":401,"phases":3602,"primaryCompletion":3531,"completion":3603,"start":3604,"enrollment":792,"conditions":3605,"interventions":3606},"NCT03033095","Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers",[95],"2018-03-28","2016-07",[3178],[3585],{"intervention":3608,"totalTrials":99,"cells":3609},"Sacubitril \u002F Valsartan Oral Tablet [Entresto]",{"EARLY_PHASE1":3610,"PHASE1":3612,"PHASE2":3614,"PHASE3":3616,"PHASE4":3618,"NA":3620},{"trials":3611,"activeCount":103},[],{"trials":3613,"activeCount":103},[],{"trials":3615,"activeCount":103},[],{"trials":3617,"activeCount":103},[],{"trials":3619,"activeCount":103},[],{"trials":3621,"activeCount":103},[3622],{"nctId":3623,"briefTitle":3624,"status":919,"phases":3625,"primaryCompletion":3626,"completion":1235,"start":3627,"enrollment":792,"conditions":3628,"interventions":3630},"NCT06149806","National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril\u002FValsartan",[],"2024-12","2021-07-01",[3629],"Complex Congenital Heart Disease",[3608],{"intervention":3632,"totalTrials":99,"cells":3633},"sildenafil",{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3638,"PHASE3":3640,"PHASE4":3642,"NA":3644},{"trials":3635,"activeCount":103},[],{"trials":3637,"activeCount":103},[],{"trials":3639,"activeCount":103},[],{"trials":3641,"activeCount":103},[],{"trials":3643,"activeCount":103},[],{"trials":3645,"activeCount":103},[3646],{"nctId":3647,"briefTitle":3648,"status":401,"phases":3649,"primaryCompletion":878,"completion":878,"start":3650,"enrollment":470,"conditions":3651,"interventions":3652},"NCT00710099","Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate in Healthy Volunteers",[95],"2008-07",[24],[3632,3653],"nitroprussiate iontophoresis",{"intervention":3653,"totalTrials":99,"cells":3655},{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3660,"PHASE3":3662,"PHASE4":3664,"NA":3666},{"trials":3657,"activeCount":103},[],{"trials":3659,"activeCount":103},[],{"trials":3661,"activeCount":103},[],{"trials":3663,"activeCount":103},[],{"trials":3665,"activeCount":103},[],{"trials":3667,"activeCount":103},[3668],{"nctId":3647,"briefTitle":3648,"status":401,"phases":3669,"primaryCompletion":878,"completion":878,"start":3650,"enrollment":470,"conditions":3670,"interventions":3671},[95],[24],[3632,3653],{"intervention":3673,"totalTrials":99,"cells":3674},"Salbutamol",{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3681,"PHASE4":3683,"NA":3685},{"trials":3676,"activeCount":103},[],{"trials":3678,"activeCount":103},[],{"trials":3680,"activeCount":103},[],{"trials":3682,"activeCount":103},[],{"trials":3684,"activeCount":103},[],{"trials":3686,"activeCount":103},[3687],{"nctId":3688,"briefTitle":3689,"status":401,"phases":3690,"primaryCompletion":3691,"completion":3691,"start":2159,"enrollment":25,"conditions":3692,"interventions":3695},"NCT02925130","Beta2-mimetic and Central Nervous System",[95],"2017-09-28",[3693,3694],"Adrenergic Beta-2 Agonist Effect","Albuterol Effect",[3673],{"intervention":3697,"totalTrials":99,"cells":3698},"Viscosupplements",{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3703,"PHASE3":3705,"PHASE4":3707,"NA":3709},{"trials":3700,"activeCount":103},[],{"trials":3702,"activeCount":103},[],{"trials":3704,"activeCount":103},[],{"trials":3706,"activeCount":103},[],{"trials":3708,"activeCount":103},[],{"trials":3710,"activeCount":103},[3711],{"nctId":3712,"briefTitle":3713,"status":919,"phases":3714,"primaryCompletion":3715,"completion":3715,"start":3716,"enrollment":470,"conditions":3717,"interventions":3719},"NCT04931121","EVALUATION OF THE CAPACITY OF A BIOMARKER BASED ON THE RAMAN ANALYSIS OF SYNOVIAL FLUID",[],"2021-08-27","2018-08-28",[3718],"Osteoarthritis, Knee",[3697],{"intervention":3721,"totalTrials":99,"cells":3722},"exercise and nutritional support",{"EARLY_PHASE1":3723,"PHASE1":3725,"PHASE2":3727,"PHASE3":3729,"PHASE4":3731,"NA":3733},{"trials":3724,"activeCount":103},[],{"trials":3726,"activeCount":103},[],{"trials":3728,"activeCount":103},[],{"trials":3730,"activeCount":103},[],{"trials":3732,"activeCount":103},[],{"trials":3734,"activeCount":103},[3735],{"nctId":3736,"briefTitle":3737,"status":919,"phases":3738,"primaryCompletion":3507,"completion":3739,"start":3740,"enrollment":2291,"conditions":3741,"interventions":3746},"NCT04746768","Frailty Syndrome of Post-cancer Treatment Eldery Patients",[95],"2024-01","2021-05-04",[3742,3743,3744,3745],"Frailty Syndrome","Exercise","Nutritional Support","Cancer",[3721],{"intervention":3748,"totalTrials":99,"cells":3749},"intensive insulin therapy",{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3754,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3751,"activeCount":103},[],{"trials":3753,"activeCount":103},[],{"trials":3755,"activeCount":103},[],{"trials":3757,"activeCount":103},[],{"trials":3759,"activeCount":103},[],{"trials":3761,"activeCount":103},[3762],{"nctId":3763,"briefTitle":3764,"status":401,"phases":3765,"completion":3766,"start":1540,"enrollment":3767,"conditions":3768,"interventions":3771},"NCT00324792","I3LTE4: Intensive Insulin Therapy and Production of LTE4 in Patients With Diabetes",[95],"2007-10",45,[3769,3770],"Diabetes Mellitus","Leucotrienes",[3748],{"intervention":3773,"totalTrials":99,"cells":3774},"Toxoplasmosis serology",{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3785},{"trials":3776,"activeCount":103},[],{"trials":3778,"activeCount":103},[],{"trials":3780,"activeCount":103},[],{"trials":3782,"activeCount":103},[],{"trials":3784,"activeCount":103},[],{"trials":3786,"activeCount":103},[3787],{"nctId":3788,"briefTitle":3789,"status":401,"phases":3790,"primaryCompletion":790,"completion":790,"start":1258,"enrollment":3791,"conditions":3792,"interventions":3794},"NCT02843438","Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis",[95],72,[3793],"Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection",[3773,3795,3796],"Anti-toxoplasmosis treatment","Anti-inflammatory treatments",{"intervention":3795,"totalTrials":99,"cells":3798},{"EARLY_PHASE1":3799,"PHASE1":3801,"PHASE2":3803,"PHASE3":3805,"PHASE4":3807,"NA":3809},{"trials":3800,"activeCount":103},[],{"trials":3802,"activeCount":103},[],{"trials":3804,"activeCount":103},[],{"trials":3806,"activeCount":103},[],{"trials":3808,"activeCount":103},[],{"trials":3810,"activeCount":103},[3811],{"nctId":3788,"briefTitle":3789,"status":401,"phases":3812,"primaryCompletion":790,"completion":790,"start":1258,"enrollment":3791,"conditions":3813,"interventions":3814},[95],[3793],[3773,3795,3796],{"intervention":3796,"totalTrials":99,"cells":3816},{"EARLY_PHASE1":3817,"PHASE1":3819,"PHASE2":3821,"PHASE3":3823,"PHASE4":3825,"NA":3827},{"trials":3818,"activeCount":103},[],{"trials":3820,"activeCount":103},[],{"trials":3822,"activeCount":103},[],{"trials":3824,"activeCount":103},[],{"trials":3826,"activeCount":103},[],{"trials":3828,"activeCount":103},[3829],{"nctId":3788,"briefTitle":3789,"status":401,"phases":3830,"primaryCompletion":790,"completion":790,"start":1258,"enrollment":3791,"conditions":3831,"interventions":3832},[95],[3793],[3773,3795,3796],{"intervention":3834,"totalTrials":99,"cells":3835},"Apolipoprotein (ApoE) detection",{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3842,"PHASE4":3844,"NA":3846},{"trials":3837,"activeCount":103},[],{"trials":3839,"activeCount":103},[],{"trials":3841,"activeCount":103},[],{"trials":3843,"activeCount":103},[],{"trials":3845,"activeCount":103},[],{"trials":3847,"activeCount":103},[3848],{"nctId":3849,"briefTitle":3850,"status":919,"phases":3851,"primaryCompletion":3852,"completion":3852,"start":3853,"enrollment":582,"conditions":3854,"interventions":3860},"NCT02843906","Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection?",[95],"2018-07","2015-07",[3855,3856,3857,3858,3859],"Senile Plaques","Tau Proteins","Alzheimer Disease","Bipolar Disorders","Mild Cognitive Impairment",[3834],{"intervention":3862,"totalTrials":99,"cells":3863},"Biological analysis",{"EARLY_PHASE1":3864,"PHASE1":3866,"PHASE2":3868,"PHASE3":3870,"PHASE4":3872,"NA":3874},{"trials":3865,"activeCount":103},[],{"trials":3867,"activeCount":103},[],{"trials":3869,"activeCount":103},[],{"trials":3871,"activeCount":103},[],{"trials":3873,"activeCount":103},[],{"trials":3875,"activeCount":103},[3876],{"nctId":3877,"briefTitle":3878,"status":919,"phases":3879,"primaryCompletion":3880,"completion":3880,"start":3881,"enrollment":19,"conditions":3882,"interventions":3884},"NCT05373524","Rheopheresis Mechanism in Hemodialysis Patients With PAD",[95],"2024-05","2022-06",[3883],"Hemodialysis",[3862],{"intervention":3886,"totalTrials":99,"cells":3887},"Tacrolimus",{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3889,"activeCount":103},[],{"trials":3891,"activeCount":103},[],{"trials":3893,"activeCount":103},[],{"trials":3895,"activeCount":103},[],{"trials":3897,"activeCount":103},[],{"trials":3899,"activeCount":103},[3900],{"nctId":3901,"briefTitle":3902,"status":919,"phases":3903,"primaryCompletion":3904,"completion":3905,"start":3906,"enrollment":2368,"conditions":3907,"interventions":3909},"NCT06307808","Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination",[],"2025-09-30","2025-10-01","2024-03-15",[2767,3114,3908],"Liver Transplantation",[3886,3910],"Belatacept",{"intervention":3910,"totalTrials":99,"cells":3912},{"EARLY_PHASE1":3913,"PHASE1":3915,"PHASE2":3917,"PHASE3":3919,"PHASE4":3921,"NA":3923},{"trials":3914,"activeCount":103},[],{"trials":3916,"activeCount":103},[],{"trials":3918,"activeCount":103},[],{"trials":3920,"activeCount":103},[],{"trials":3922,"activeCount":103},[],{"trials":3924,"activeCount":103},[3925],{"nctId":3901,"briefTitle":3902,"status":919,"phases":3926,"primaryCompletion":3904,"completion":3905,"start":3906,"enrollment":2368,"conditions":3927,"interventions":3928},[],[2767,3114,3908],[3886,3910],{"intervention":3930,"totalTrials":99,"cells":3931},"soluble Ve cadherin",{"EARLY_PHASE1":3932,"PHASE1":3934,"PHASE2":3936,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3933,"activeCount":103},[],{"trials":3935,"activeCount":103},[],{"trials":3937,"activeCount":103},[],{"trials":3939,"activeCount":103},[],{"trials":3941,"activeCount":103},[],{"trials":3943,"activeCount":103},[3944],{"nctId":3945,"briefTitle":3946,"status":401,"phases":3947,"primaryCompletion":1153,"completion":1153,"start":3948,"enrollment":3949,"conditions":3950,"interventions":3953},"NCT02212249","Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis",[95],"2014-05",85,[3951,3952],"Primary Raynaud Disease","Systemic Sclerosis",[3930],{"intervention":3955,"totalTrials":99,"cells":3956},"Blood and respiratory fluids sampling",{"EARLY_PHASE1":3957,"PHASE1":3959,"PHASE2":3961,"PHASE3":3963,"PHASE4":3965,"NA":3967},{"trials":3958,"activeCount":103},[],{"trials":3960,"activeCount":103},[],{"trials":3962,"activeCount":103},[],{"trials":3964,"activeCount":103},[],{"trials":3966,"activeCount":103},[],{"trials":3968,"activeCount":103},[3969],{"nctId":3970,"briefTitle":3971,"status":401,"phases":3972,"primaryCompletion":3973,"completion":3974,"start":3975,"enrollment":2418,"conditions":3976,"interventions":3978},"NCT02853006","Study on Fluids Associated to Lung Cancer",[95],"2019-09","2020-02","2015-06",[3977],"Lung Cancer",[3955]]